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Aminoglycosides represent an important class of antimicrobial agents. The prevalence 
of aminoglycoside resistance among Gram-negative bacteria in Norway is low, but an 
increased prevalence among clinical isolates of Escherichia coli has been observed during the 
last years. The most prevalent resistance mechanism is aminoglycoside modifying enzymes. 
In addition, resistance may occur when bacteria produces 16S rRNA methylases, which 
causes high level and broad-spectrum aminoglycoside resistance. 
 In this study, we analysed the susceptibility pattern of different aminoglycosides in 
different Norwegian strain collections of E. coli, Klebsiella spp. and Pseudomonas 
aeruginosa. Among E. coli and Klebsiella spp. isolates from the Norwegian surveillance 
programme for antimicrobial resistance (NORM) 2009 the prevalence of reduced 
susceptibility to tobramycin (4.1%) was slightly higher compared to gentamicin (3.8), in 
blood culture isolates of E. coli and 2% and 1.4% in in blood culture isolates of Klebsiella 
spp., respectively. The prevalence of reduced susceptibility to amikacin was low in both 
species; 0.6% in E. coli and 0.4% in Klebsiella spp. In a collection of ESBLA-positive 
Enterobacteriaceae isolates the prevalence of reduced susceptibility was much higher with 
56% and 44% of the isolates showing reduced susceptibility to tobramycin and gentamicin, 
respectively. The prevalence of reduced susceptibility to amikacin (7%) was also lower than 
for tobramycin and gentamicin in the ESBLA-positive isolates. The same pattern was also 
observed in the collection of carbapenem non-susceptible P. aeruginosa isolates.  
 In both Enterobacteriaceae collections the aminoglycoside modifying enzymes 
AAC(3)-II and AAC(6’)-Ib were the dominating enzymes causing aminoglycoside resistance. 
The 16S rRNA methylases rmtB and rmtD were detected in one E. coli and one P. aeruginosa 
isolate resistant to all aminoglycosides tested, respectively. 
 Three different methods for detection of reduced susceptibility were used; Etest, 
EUCAST disk diffusion and VITEK2 AST. The results from the three methods were 
compared. Discrepancies were mainly observed when comparing Etest and EUCAST disk 
diffusion for detecting tobramycin resistance in Enterobacteriaceae, and comparing Etest and 
EUCAST disk diffusion for detecting gentamicin resistance in P. aeruginosa. 
 In conclusion, aminoglycoside resistance in Norway is low, but increasing. 
Worryingly, aminoglycoside resistance is coupled with other resistance mechanisms such as 
ESBLA resulting in multidrug resistance limiting treatment options. Method comparison 






1.1 Antimicrobial agents  
1.1.1 Brief historical background 
Antimicrobial agents have since their discovery during the 20th century, saved lives 
and eased the suffering of millions of people. Many serious infectious diseases have been 
brought under control by these antimicrobial agents, and thus contributed to major gains in 
life expectancy experienced during the latter part of the last century.  
 
In September 1928, Alexander Fleming by coincidence discovered the fact that the 
mold Penicillum inhibited the growth of Staphylococci, and decided to investigate this 
phenomenon further(17). This is considered the onset of the antibiotic era. But the findings of 
Fleming were actually a rediscovery of the observations of John Tyndall, an English physicist 
in 1875(17). During an experiment Tyndall wanted to find out whether bacteria were evenly 
dispersed in the atmosphere or aggregated in clouds, by incubating open test tubes containing 
broth. After incubation a number of the tubes remained clear, indicating that bacteria were not 
evenly dispersed in the atmosphere. But more importantly he observed a Penicillum on the 
surface of the broth in some of the tubes. A battle was in progress between the bacteria and 
the mold, and “in every case where the mold was thick and coherent, the bacteria died or 
became dormant and fell to the bottom as a sediment”. Tyndall did not explore his 
observations any further, and the power of Penicillum remained unknown until Fleming 
observed the Penicillin’s ability to kill bacteria(17). In the spring of 1940, Florey and Chain 
from Oxford University were able to make a small amount of yellowish powder from the 
mold discovered by Fleming. This initiated the first commercial production of penicillin. In 
1945, the Nobel prize in medicine was awarded to Fleming, Florey and Chain(26).  
 
During the years 1940-1960 many other antimicrobial agents were identified and 
developed, as Figure 1 shows. Aminoglycosides, other β-lactams than penicillin, tetracycline, 
macrolides, and glycopeptides are examples of new classes of antibiotics developed. But 
between the introduction of quinolones in 1962 and the next new structural class of antibiotic; 
the oxazolidinones, there was a gap of 40 years(48). Unfortunately, few large pharmaceutical 
companies are active in the antibacterial infectious disease arena, making the future unsure 
regarding development of new antibiotics.  
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Figure 1. Timeline showing development of antimicrobial agents during  the years 1908 – 2003(52).  
 
 
1.1.2 Antimicrobial agents 
Antimicrobial agents are molecules that stop microbes, both bacteria and fungi, from 
growing or kill them outright. They are often products of soil bacteria and fungi, with the 
major group of antibiotic-producing bacteria being the actinomycetes(50). The majority of 
antimicrobial agents in clinical use today are derivates from natural products of fermentation 
or chemically modified (i.e semi-synthetic) to improve their antibacterial and pharmacologic 
properties. In addition, some agents like the quinolones are totally synthetic(31). 
 
Antimicrobial agents can be classified as bactericidal, exemplified by penicillin or 
bacteriostatic, exemplified by chloramphenicol. Bactericidal agents cause bacterial cell death, 
while bacteriostatic agents prevent the bacteria from growing(50). Classification of 
antimicrobials may also be done according to their mechanisms of action (Table 1); (I) 
interference with cell wall synthesis, (II) inhibition of protein synthesis, (III) interference with 
nucleic acid synthesis, and (IV) inhibition of a metabolic pathway. Disruption of the bacterial 






Table 1. Mechanisms of action of antimicrobial agents (adapted from Tenover 2006(45)) 
Mechanism of action Antimicrobial agent(s) 
1. Interference with cell wall synthesis β-lactams: penicillins, cephalosporins, carbapenems, 
monobactams 
Glycopeptides: vancomycin, teicoplanin 
2. Inhibition of protein synthesis: 
Binding to 50S ribosomal unit 
Binding to 30S ribosomal unit 
Macrolides, chloramphenicol, clindamycin, 
quinopristin-dalfopristin, linezolid 
Aminoglycosides, tetracyclines 
3. Interference with nucleic acid synthesis: 
Inhibition of  DNA synthesis 
Inhibition of  RNA synthesis 
Fluoroquinolones, rifampicin 
4. Inhibition of a metabolic pathway Sulfonamides, folic acid analogous 
5. Disruption of bacterial membrane structure Polymyxins, daptomycin 
 
 
1.2 Aminoglycosides  
1.2.1 Discovery of aminoglycosides 
Streptomycin was the first aminoglycoside to be identified and characterized by 
Selman Waksman in 1944. In contrast to penicillin which was isolated from fungi, 
streptomycin was the first antimicrobial to be isolated from a bacterial source. The discovery 
of streptomycin was a landmark in the history of antimicrobials, since it was the first effective 
treatment for tuberculosis, a disease that had caused tremendous human suffering for 
centuries(9). 
 
A number of aminoglycosides have been isolated and tested during the years, but only 
the aminoglycosides investigated in this study will mainly be further discussed. The source 
and year of isolation of the aminoglycosides included in this study are listed in Table 2. In 
Norway only gentamicin and tobramycin are licensed for general use, while amikacin and 
netilimicin are not marketed. 
 
 
Table 2. The source and year of isolation of the aminoglycosides included in this study. 
(adapted from Aminoglycoside antibiotics. From chemical biology to drug discovery(9)) 
Aminoglycoside Isolated/synthesized from Year of isolation 
Streptomycin Streptomyces griseus 1944 
Kanamycin Streptomyces kanamyceticus 1957 
Gentamicin Micromonospora purpureochromogenes 1963 
Tobramycin Synthesized from kanamycin 1967 
Amikacin Synthesized from kanamycin 1972 
Arbekacin Synthesized from dibekacin (syntethic derivative 
from kanamycin) 
1973 
Isepamicin Synthesized from gentamicin 1975 





1.2.2 Classification of aminoglycosides 
Aminoglycosides are a complex family of compounds and the classification can be 
based on the chemical structure. There are different structural classes of aminoglycosides, 
characterised by having an aminocyclitol nucleus (streptamine, 2-deoxystreptamine (DOS) or 
streptidine) linked to amino sugars through glycosidic bonds(35). There are two main classes 
















Figure 2. The chemical structure of streptomycin, including (from left to right) aminocyclitol nucleus 




(I) Streptomycin consists of three sugar constituents: an aminocyclitol (streptidine) 
connected to a pentose (streptose) which again is connected to glucosamine(49) (Figure 2). 
Derivatives of streptomycin have different semi-synthetic modifications as R-groups on the 
pentose. Streptomycin has HCO as the R-group, while derivates of streptomycin has other R-
groups at this position. 
 
(II) The deoxystreptamine class has the aminocyclitol nucleus streptamine placed in 
centre of the molecule. This class is divided into two groups according to whether the sugar 
constituents are placed at 4,5 or 4,6 position of the aminocyclitol nucleus(9). In kanamycin 
(Figure 3), an aminoglycoside belonging to the 4,6 substituted deoxystreptamine class, the 
aminocylitol deoxystreptamine is the central ring, with glucosamine connected at position 4 
and a hexose is connected at position 6 of the aminocyclitol ring. Different R-groups placed 
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on different positions of the sugars, define derivates of kanamycin. Kanamycin was the first 












Figure 3. The chemical structure of kanamycin, with deoxystreptamine as the aminocyclitol nucleus, 




Streptomyces, Micromonospora, Bacillus, and other bacterial genera have been shown 
to produce aminoglycoside-aminocyclitol antibiotics(9). The compounds derived from 
Streptomyces are named with the suffix “-mycin” (e.g tobramycin), while compounds derived 
from Micromonospora are named with the suffix “-micin” (e.g. gentamicin). Gentamicin is 
special among the aminoglycosides as it is not a single molecule, but consists of three major 
and several minor components(24). The major components of the drug complex are 









1.2.3 Antibacterial characteristics and toxicity of aminoglycosides 
Aminoglycosides exhibit in vitro activity against a broad-spectrum of clinically 
important Gram-negative bacteria such as Escherichia coli, Klebsiella spp., Pseudomonas 
spp., Shigella spp., Salmonella spp., Enterobacter spp., Citrobacter spp., Acinetobacter spp., 
Proteus spp., Serratia spp., and Morganella spp as well as the Gram-positive bacteria 
Staphylococcus aureus and some streptococci(47). No in vitro activity has however been 
predicted against Streptocccus pneumoniae, Neisseria gonorrhoeae, Burkholderia cepacia, 
Stenotrophomonas maltophilia, and anaerobic microorganisms. Aminoglycosides only give 
adequate activity against enterococci as long as they are used synergistically with a cell wall-
active antibiotic, such as a β-lactam or vancomycin. 
 
Aminoglycosides exhibit several characteristics that make them useful as 
antimicrobial agents(47). The bactericidal activity of aminoglycosides depends more on their 
concentration than on the duration of bacterial exposure to inhibitory concentrations of the 
antimicrobial agent. The potential of aminoglycosides to kill bacteria depends on the 
concentration of the antibiotic, and increases with increasing concentrations. In addition, 
aminoglycosides continue to kill bacteria even after the aminoglycoside is detectable, 
exhibiting an important post-antibiotic effect. This is probably due to a strong, irreversible 
binding to the ribosome. The synergistic bactericidal activity in combination with 
antimicrobial agents inhibiting cell wall biosynthesis is another important characteristic of 
aminoglycosides. Synergism is probably due to the enhanced intracellular uptake of 
aminoglycosides caused by the increased permeability of bacteria after incubation with cell 
wall synthesis inhibitors. 
 
Unfortunately, aminoglycosides can give toxic responses such as ototoxicity and renal 
toxicity. Streptomycin, among other aminoglycosides targets sensory hair cells of the inner 
ear and can lead to hair-cell degeneration and permanent hearing loss in up to five % of 
patients(9). Concentration-dependent bactericidal activity and post-antibiotic effect in 
combination with the risk of ototoxicity and renal toxicity are the major reasons for once-




1.2.4 Mechanism of action of aminoglycosides 
Aminoglycosides attack the bacteria in a two-step process. Firstly, uptake of 
aminoglycosides into the bacteria is an important process for their biological activity. 
Secondly, inside the bacterial cell the aminoglycoside binds to the ribosome and inhibits 
protein synthesis(47). 
 
1.2.4.1 Bacterial uptake of aminoglycosides 
The bacterial cell wall is penetrated by the aminoglycoside in a three-step process; an 
energy-independent step followed by two energy-dependent steps(35). 
 
In the energy-independent step the aminoglycosides binds to the surface-anionic 
compounds of the bacterial cell wall such as lipopolysaccharide, phospholipids and outer 
membrane proteins in Gram-negatives and teichoic acids and phospholipids in Gram-
positives(35). The binding to the anionic sites on the outer membrane, results in displacement 
of Mg2+ and Ca2+ ions that link adjacent lipopolysaccharide molecules. The effect on the 
bacterial cell is increased permeability that leads to the so-called “self-promoted uptake” 
penetration of aminoglycoside molecules into the periplasmic space. 
 
The initial electrostatic surface binding is followed by the energy-dependent phase I. A 
small number of aminoglycoside molecules cross the cytoplasmic membrane in a process that 
requires a threshold transmembrane potential generated by a membrane-bound respiratory 
chain(35). This explains why anaerobes, which have a deficient electron transport system, are 
intrinsically resistant to aminoglycosides. The aminoglycoside molecules that reach the 
cytoplasm binds to the ribosome and results in misreading of the mRNA and production of 
misfolded membrane proteins. These membrane proteins cause damage to the integrity of the 
cytoplasmic membrane.  
 
Finally, the loss of membrane integrity triggers the energy-dependent phase II. The 
damaged cytoplasmic membrane results in an accelerated rate of uptake of aminoglycoside 
molecules. The aminoglycoside accumulates rapidly in the cytoplasm and irreversibly 
saturates all ribosomes, resulting in cell-death. The higher concentration of the 
aminoglycoside, the more rapid is the onset of energy-dependent phase II and the death of the 
bacterial cell(35,47) 
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1.2.4.2 Molecular mechanism of action  
The ribosome has an important role in translating mRNA into proteins in the bacterial 
cell, and consists of two subunits; designated 50S and 30S(47). The large subunit (50S) is 
made up by two RNA molecules; 5S and 23S RNAs and about 30 proteins. The small subunit 
(30S) is made up by 16S RNA and 20 to 21 proteins. During proteins synthesis, the ribosome 




Figure 5. Protein synthesis where tRNA attaches to the A-site at the small ribosome unit and incorporates 
amino acids into the growing polypeptide chain. (kentsimmons.uwinnipeg.ca/cm1504/Image283.gif) 
 
 
Transfer RNAs (tRNAs) are small stable RNAs to which specific amino acids are 
attached. The tRNA with the amino acid attached enters the ribosome and basepairs through 
its anticodon sequence with a 3-nucleotide codon sequence in the mRNA to insert the correct 
amino acid into the growing polypeptide chain(43) (Figure 5). The 30 S ribosome has three 
functionally important tRNA binding sites; A-site (for acceptor), P-site (for peptidyl) and E-
site (for exit). The A-site has a great ability to discriminate correct and incorrect binding of 
tRNA, leading to a high fidelity of translation(47). The aminoglycosides bind to specific sites 
of the 30S ribosomal subunit and interfere with protein synthesis. Most aminoglycosides of 
the 2-deoxystreptamine aminocyclitol class (e.g. gentamicin) bind specifically to the A-site 
 17 
(tRNA binding site) on the 16S rRNA. Streptomycin, belonging to the streptamine 
aminocyclitol class, also binds to the A-site, but in addition binds to rRNA and other 
proteins(9). 
 
1.3 Antibiotic resistance 
The major advances in antimicrobial drug development beginning through the middle 
of the 20th century, made a great difference in the battle between humans and the multitude of 
microorganisms that causes infection and disease. This made the humans believe they could 
win the battle. But almost as soon as the antimicrobials were taken into use, the bacteria 
responded by showing various forms of resistance. As antimicrobial usage has increased over 
the years, the bacteria have responded by developing different forms of resistance. 
 
Microbes that are resistant to one or several of the antimicrobial agents available are 
emerging and disseminating worldwide. The World Health Organisation (WHO) launched in 
2001, WHO Global Strategy for Containment of Antimicrobial Resistance, the first global 
strategy for combating the serious problems caused by the emergence and spread of 
antimicrobial resistance. The strategy recognizes that antimicrobial resistance is a global 
problem that must be addressed in all countries.  
(http://www.who.int/mediacentre/factsheets/fs194/en/  Access date: 230910). 
 
Bacteria may be intrinsically resistant to one or more classes of antimicrobial agents. 
In these cases, all strains of a bacterial species are resistant to those antimicrobial agents(45). 
Resistance can also be acquired by de novo mutations or by the acquisition of resistance genes 
from other organisms. Acquired resistance is not present in the entire species population, but 
may proliferate and spread under selective pressure. 
 
There are several different mechanisms responsible for development of antibiotic 
resistance(45); (I) The bacteria may acquire genes encoding enzymes that inactivate the agent 
before it can have an effect, (II) the bacteria may acquire efflux pumps that pump the agent 
out of the cell before it reaches its target site, (III) the bacteria may acquire mutations that 
limit access of antimicrobial agents to the intracellular target site via down-regulation of porin 
genes, and finally (IV) the bacteria may acquire several genes for a metabolic pathway which 
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produces altered cellular targets in the bacteria which no longer contain the binding site of the 
antimicrobial agent.  
 
Normally susceptible populations of bacteria may become resistant to antimicrobial 
agents through mutations and selection, or by acquiring resistance-encoding genes from other 
bacteria(45). Bacteria that carry resistance-conferring mutations are selected by antimicrobial 
use, which allows the resistant strains to survive and proliferate, while the susceptible strains 
are killed. This is termed vertical gene transfer. Bacteria may also develop resistance through 
acquisition of new genetic material from other resistant organisms, and this is termed 
horizontal gene transfer. 
 
1.3.1 Horizontal gene transfer 
Horizontal gene transfer is an event in which an organism incorporates genetic 
material from another organism, without reproduction(43). It may occur between strains of 
the same species or between different bacteria or genera. DNA can be transferred among 
bacteria in three ways: transformation, conjugation and transduction (Figure 6). DNA is 
derived from a donor bacterium and taken up by a recipient bacterium, and the off-springs are 










Uptake of naked DNA from the environment is called transformation, and this 
mechanism of bacterial gene transfer was the first to be discovered(43).  
The general steps of natural transformation differ depending on whether the bacterium 
is Gram-positive or Gram-negative, since the Gram-positive bacteria lack the outer 
membrane. In the Gram-negative bacteria: I) double stranded DNA (dsDNA) is bound to the 
outer surface of the bacterium, II) DNA is moved across the cell wall and outer membrane, 
III) one of the DNA strands is degraded by nucleases and IV) the single stranded DNA 
(ssDNA) is transferred into the cytoplasm across the inner membrane(43). The steps of 
transformation in Gram-positive bacteria are quite similar, except that transport through the 
outer membrane is not necessary. When inside the cytoplasm, the ssDNA might (I) synthesize 
the complementary strand and establish itself as a plasmid, (II) stably integrate into the 
recipients chromosome by homologous recombination or (III) be degraded. Bacteria made 
artificially competent can take up double stranded DNA (dsDNA). The role of natural 
transformation is thought to be DNA repair, nutrition and recombination to increase diversity. 
 
1.3.1.2 Conjugation 
The ability to transfer DNA through cell-to-cell contact is called conjugation, and was 
first observed by Joshua Lederberg and Edward Tatum in 1947(43). This process is associated 
with transfer of plasmids and chromosomal genetic elements.   
 
The transfer systems of plasmids and chromosomal genetic elements are associated 
with tra-genes(43). These systems are similar between plasmids and chromosomal genetic 
elements. In plasmids tra-genes can also act on another plasmid in the same cell, they are 
trans-acting. In addition, the plasmid must have an oriT site for transfer. The tra-genes encode 
Mpf (Mating Pair Formation) components and Dtr (DNA Transfer and Replication) 
components. The function of the Mpf is to hold the donor and the recipient cell together 
during mating process, and to form a channel through which proteins and DNA are transferred 
during mating. It also includes proteins which communicate with the Dtr-system. The Dtr 
components prepare the plasmid for transfer. In brief, the conjugation process involves: I) The 
donor cell produces a pilus which makes contact with the recipient cell, II) the self-
transmissible plasmid encodes a relaxase, which makes a single-stranded nick at the oriT site 
of the plasmid, III) a plasmid encoded helicase separates the strands of the plasmid DNA, IV) 
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relaxase attached to the 5’ end of the ssDNA transports the strand into the recipient, V) inside 
the recipient, the relaxase recycles the ssDNA, and a complementary strand is made, and VI) 
a complementary strand of the remaining ssDNA in the donor cell is made.  
 
1.3.1.3 Transduction 
Transduction is the third known process of horizontal gene transfer, where DNA is 
transferred from one cell to another by a virus that infects bacteria, a so-called 
bacteriophage(43). Transduction is known to occur in a variety of bacteria, such as 
Salmonella spp., Staphylococcus spp., Escherichia spp., Pseudomonas spp., and 
Desulfovibrio spp.  
 
In generalized transduction, almost any gene on the chromosome from the donor cell 
can be transferred to the recipient(43). When a bacterial cell is infected by a phage, the lytic 
cycle may be initiated. The lytic cycle is a series of steps where the virus replicates inside the 
host cell and cause lysis of the host. During the replication process, parts of host DNA might 
accidentally be packed into the virus genome. During cell lysis, these particles, called 
transducing particles, will be released. Transducing particles containing DNA from their 
previous host can then infect another cell. The accidentally packed DNA from the host 
bacteria can then undergo genetic recombination with the DNA of the new host.  
 
Specialised transduction only occurs in some temperate viruses, such as phage lambda 
of E. coli(43). Here the phage DNA becomes integrated into the host DNA, and the phage 
enters the lysogenetic phase, where the viral DNA replication is under the control of the 
bacterial host chromosome. Upon induction, the viral DNA is excised from the host DNA and 
starts replicating. In some cases, the viral DNA is not excised correctly, and some of the 
adjacent host DNA is incorporated in the virus DNA.                                                                                                                                                                                                                                                                                     
 
1.3.1.4 Plasmids 
Plasmids are DNA molecules that exist free of the chromosome in the bacterial cell 
and replicate independently of the chromosome(43). Most plasmids are circular, but some are 
linear. The number of plasmids in a cell may vary from one copy to hundreds of copies in a 
single cell and the cell can also harbour different plasmids. The size of plasmids can vary 
from a few hundred basepairs to almost the length of the chromosome. Plasmids do generally 
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not harbour genes essential to bacterial growth, but genes which are beneficial for the 
bacterium harbouring them, such as genes coding for antibiotic resistance.  
Some plasmids are self-transmissible and are able to transfer themselves to other 
bacterial cells in the process called conjugation(43). Plasmids that encode functions needed 
for transfer of themselves are called self-transmissible or conjugative plasmids. Other 
plasmids do not encode all the genes required for transfer and consequently need the help of 
transferable plasmids to move between different bacteria. Self-transmissible plasmids 
probably exist in all types of bacteria, but the most studied bacteria are the Gram-negative 
Escherichia coli and the Gram-positive Enterococcus spp., Streptococcus spp., Bacillus spp., 
Staphylococcus spp., and Streptomyces spp(43).  
 
Plasmid-associated resistance genes have been detected for almost all clinically 
available antimicrobials, and a single plasmid may mediate resistance to multiple 
antimicrobials and may be shared among different bacterial genera(43). In addition to 
carrying resistance genes, plasmids can serve as vehicles for other genetic elements important 




Transposons are DNA sequences that are able to move from one place in DNA to a 
different place with the help of the enzyme transposase(43). This movement is called 
transposition. The smallest transposons in bacteria are IS elements, which contain only the 
genes required for their own transposition. Transposons are known to carry antibiotic 




Integrons are genetic systems responsible for the gathering of resistance determinants 
in mobile genetic elements such as plasmids and transposons(12). These mobile elements 
contain a gene for integrase and an att site for integration of gene cassettes, often coding for 
antibiotic resistance. A promoter is also present to allow transcription of cassette genes 
inserted into the att site(43). 
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1.4 Aminoglycoside resistance 
Aminoglycoside resistance occurs by three different mechanisms; (I) modification of 
the rRNA and ribosomal protein targets, (II) reduced uptake and increased efflux, and (III) 
aminoglycoside-modifying enzymes(22). The latter mechanism has by far been the most 










1.4.1 Resistance by target modification 
Resistance to aminoglycosides by target modification can occur in two ways: either by 
alteration of the target or by enzyme-catalysed target modification(9).  
 
Aminoglycosides bind to the tRNA A-site of the ribosome where the codon-anticodon 
interactions occur. In most cases this will disrupt the ribosomal discrimination of cognate 
codon-anticodon pairs, leading to impairment of the genetic code and production of missense 
proteins. Most of the aminoglycosides of the 2-deoxystreptamine class (e.g. gentamicin) bind 
to the 16S rRNA of the 30S ribosomal subunit in the codon-decoding A-site. As a result, point 
mutations in the 16S rRNA can lead to impairment of codon-anticodon pairing and 
consequently lead to aminoglycoside resistance(9). 
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Streptomycin which belong to the streptamine class of aminoglycosides, also binds in 
the A-site at the 16S rRNA, but in addition streptomycin binds to other rRNA and ribosomal 
proteins. As a consequence, mutations in 16S rRNA and ribosomal proteins may result in high 
level resistance to streptomycin(9). 
 
Many aminoglycoside-producing organisms, including Streptomyces spp. and 
Micromonospora spp. are capable of expressing 16S rRNA methylases, which are able to 
methylate nucleotides within the A-site of the 16S rRNA, conferring high level and broad-
spectrum aminoglycoside resistance(16) (Figure 8). This is an efficient way of avoiding 
inhibition of their own protein synthesis, and several intrinsic 16S rRNA methylases have 
been described among actinomycetes. In addition, 16S rRNA methylases associated with 
mobile genetic elements such as plasmids and transposons have been identified in clinically 
relevant strains of Gram–negative bacteria, such as Klebsiella pneumoniae, E. coli, and 




Figure 8.  16S rRNA methylases methylate nucleotides within the A-site of the 16S rRNA conferring 







1.4.2 Resistance by reduced uptake and increased efflux 
Aminoglycoside resistance can also be due to mechanisms that limit the uptake of 
aminoglycosides to the cytoplasm. To gain access to the target ribosome the aminoglycosides 
have to traverse the plasma membrane and in the case of Gram-negative bacteria also the 
outer membrane(9). This uptake of aminoglycosides requires respiration, generated by an 
electrical potential across the cytoplasmic membrane. Thus, mutations in electron chain 
components reducing the electric potential can lead to reduced uptake of aminoglycosides and 
resistance.  
  
In species such as Pseudomonas, Burkholderia, and Stenotrophomonas 
transmembrane efflux systems have been identified as a significant mechanism for 
aminoglycoside resistance(9). Different efflux systems have been described with the 
resistance-nodulation-division family (RND) as the dominant class responsible for pumping 
out aminoglycoside before they reach the ribosomes. 
 
 
1.4.3 Aminoglycoside-modifying enzymes (AMEs) 
The major mechanism of aminoglycoside resistance in clinical isolates of both Gram-
negative and Gram-positive bacteria is enzymatic modification of amino- or hydroxyl-groups 
of the aminoglycosides(47). Enzymatic modification of aminoglycosides results in reduced or 
abolished binding of the aminoglycoside molecule to the ribosome and failure in trigging 
energy-dependent phase II.  
 
Aminoglycoside-modifying enzymes (AMEs) can be divided into three families; 
aminoglycoside N-acetyltransferases (AACs), aminoglycoside O-phosphotransferases 
(APHs), and aminoglycoside O-nucleotidyltransferases (ANTs). Many of the AMEs results in 
clinical relevant resistance, but in general only the APHs produce high level of resistance(47). 
 
The different aminoglycoside modifying enzymes investigated in this study together 





Table 3. Aminoglycoside modifying enzymes investigated in this study, together with their antibiotic 
resistance profile. 
AME Subclass Antibiotic resistance profile 
AAC AAC(6’)-I Amikacin, gentamicin C1a and C2 
 AAC(3)-Ia Gentamicin 
 AAC(3)-II Gentamicin, netilmicin, tobramycin 
ANT ANT(2’’)-Ia Gentamicin, tobramycin, kanamycin 
 ANT(4’)-IIb Amikacin, tobramycin, isepamycin 
 
 
An impressive number of AMEs has been identified to date. Unfortunately, there are 
inconsistencies in the nomenclature of genes and protein names of these enzymes(35). This 
study will follow the nomenclature proposed by Shaw and colleagues(41), where each 
enzyme family is given a three-letter identifier. Each of the families is further divided into 
classes, designated by the site of modification, indicated in parenthesis. The classes are 
further subdivided into enzyme types using Roman numerals, which specify unique resistance 
phenotypes. Enzymes of the same class and type that produce the same phenotype but are 
encoded by different genes, are designated by a lowercase letter. As example, AAC(6’)-Ia 
represents an N-acetyltransferase that catalyses acetylation at the 6’ position, and produces 





Figure 9. Representative aminoglycosides and modification sites by AAC, ANT, and APH(35).  
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1.4.3.1 Aminoglycoside N-acetyltransferases (AACs) 
 
Aminoglycoside N-acetyltransferases (AACs) belong to a superfamily of proteins, 
which includes about 10,000 proteins. AACs catalyse the acetylation of –NH2 groups in the 
aminoglycoside molecule, using acetyl coenzyme A as a donor substrate. There are four 
classes of AACs, and the acetylation occur in the 1 [AAC(1)], 3 [AAC(3)], 2’ [AAC(2’)], or 
6’ [AAC(6’)] position of the aminoglycoside(35) (Figure 9). 
 
AAC(6’) enzymes are the most common enzymes among the AACs, and are present in 
both Gram-negative and Gram-positive bacteria. The genes coding for AAC(6’) have been 
found located on plasmids and chromosomes and are often part of mobile genetic elements. 
There are two main subclasses; AAC(6’)-I and AAC(6’)-II. The first subclass, AAC(6’)-I 
shows activity against gentamicin C1a and C2 and amikacin, and is probably the most 
clinically relevant acetyltransferase. AAC(6’)-II shows high activity against all three forms of 
gentamicin (C1, C1a and C2), but not amikacin(35). One enzyme variant of AAC(6’)-I 
designated AAC(6’)-Ib-cr also shows activity against fluoroquinolones, and can be considered 
a third subclass(35). AAC(6’)-Ib-cr is probably the first enzyme discovered able to confer 
resistance to two different classes of antimicrobial agents of which one is purely 
synthetic(36). 
 
The AAC(3) class of AACs consists of nine subclasses (I-X), and all of them are 
identified in Gram-negative bacteria. Subclass V was eliminated after confirmation that this 
enzyme was identical to AAC(3)-II. AAC(3)-I includes five enzymes (AAC(3)-Ia to AAC(3)-
Ie) and confers resistance to gentamicin and other aminoglycosides such as sisomycin and 
fortimicin. These enzymes are present in a large number of Enterobacteriaceae and other 
Gram-negative clinical isolates and are all found encoded as part of gene cassettes in 
integrons. AAC(3)-II includes three enzymes AAC(3)-IIa, -IIb, and -IIc which confer 
resistance to gentamicin, netilmicin, tobramycin, sisomycin, and dibekacin, and their genes 
are located on plasmids in integrons as gene cassettes often associated with transposons. 
AAC(3)-II enzymes has been identified in different Gram-negative genera(35). 
 
Other important AACs include AAC(1) enzymes which have been found in E. coli, 
Campylobacter spp. and an actinomycete, and AAC(2’) enzymes that have been found in 
Gram-negative bacteria and Mycobacterium(35). The genetic location of AAC(2’) 
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determinants is the chromosome, while the genetic location of AAC(1) encoding genes has 
not been determined. It has been suggested by Sunada et al(44) that the gene is located in the 
chromosome, but these results have not been confirmed.  
 
 
1.4.3.2 Aminoglycoside O-nucleotidyltransferases (ANTs) 
Aminoglycosides are inactivated by aminoglycoside O-nucleotidyltransferases (ANTs) 
through catalysation of the transfer of an adenosine monophospate (AMP) group from the 
donor substrate adenosine triphosphate (ATP) to a hydroxyl group on the aminoglycoside 
molecule. There are five classes of ANTs that catalyze adenlylation at the 6 [ANT(6)], 9 
[ANT(9)], 4’ [ANT(4’)], 2’’ [ANT(2’’)], and 3‘’ [ANT(3’’)] positions(35) (Figure 9). 
 
ANT(3’’) enzymes are the most commonly found enzyme of the ANT family, and at 
least 22 genes belonging to this class have been identified among both Gram-positive and 
Gram-negative bacteria. These genes confer resistance to spectinomycin and streptomycin, 
exist as gene cassettes and are part of a large number of integrons, plasmids and 
transposons(35).  
 
ANT(2’’) is present in enterobacteria and non-fermentative Gram-negative bacteria 
and mediates resistance to gentamicin, tobramycin, kanamycin, dibekacin, and sisomicin. The 
only enzyme in this class is ANT(2’’)-Ia of which the gene is widely distributed as a gene 
cassette product in class 1 and 2 integrons commonly located on plasmids and transposon 
structures(35). 
 
ANT(4’) includes two subclasses, I and II. The ANT(4’)-I gene has been found in 
plasmids in Gram-positive bacteria, while ANT(4’)-II enzymes have been identified in Gram-
negative bacteria. These enzymes confer resistance to tobramycin, amikacin and isepamicin, 
and subclass I also confers resistance to dibekacin. Two ANT(4’)-II enzymes have been 
described; ANT(4’)-IIa was identified encoded on plasmids from Pseudomonas and 
Enterobacteriaceae and ANT(4’)-IIb was encoded in a Pseudomonas aeruginosa 
transposon(35). 
 
ANT(6) enzymes are widely spread among Gram-positive bacteria and confer 
resistance to streptomycin. Genes coding for ANT(6) enzymes are found in plasmids, 
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transposons and integrons. In the ANT(9) class, two enzymes have been described in Gram-
positive bacteria, conferring resistance to spectinomycin. The genes coding for these enzymes 
were located on a transposon(35). 
 
 
1.4.3.3 Aminoglycoside O-phosphotransferases (APHs) 
Aminoglycoside O-phosphotransferases (APHs) catalyse the transfer of a phosphate 
group to the aminoglycoside molecule. Seven classes of enzymes have been identified in 
clinical isolates and aminoglycoside-producing organisms. The phosphate group are 
introduced at the 4 [APH(4)], 6 [APH(6)], 9 [APH(9)], 3’ [APH(3’), 3’’ [APH(3’’)], 2’’ 
[APH(2’’)], and 7’’ [APH(7’’)] position of the aminoglycoside molecule(35) (Figure 9). 
 
The largest group of APH enzymes is the APH (3’) class which can be divided in 
seven sub-classes I-VII. They have been identified in several different Gram-negative, Gram-
positive and aminoglycoside-producing organisms, and their encoding genes are located on 
plasmids and chromosomes. The resistance profile differs in the different sub-groups(35). 
 
Both APH(6) and APH(3’’) confer resistance to streptomycin, and the genes coding 
for the enzymes are both located on chromosomes, transposons and plasmids. APH(4) and 
APH(7’’) both confer resistance to hygromycin which is not clinically relevant. The enzymes 
in class APH(9) are encoded by genes located on the chromosome, and confer resistance to 
spectinomycin. In the APH(2’’) class, the enzymes confer resistance to gentamicin in Gram-
positive bacteria. This class can be divided into four subclasses I-IV, and the genes encoding 
these enzymes are located on plasmids and chromosomes(35). 
 
 
1.5 ESBL (extended-spectrum β-lactamases) 
As the genes encoding AMEs are often located on plasmids they can be associated 
with other types of resistance genes conferring resistance to other antimicrobial agents. This is 
particularly observed with genes encoding ESBLA-enzymes resulting in isolates resistant to 
both aminoglycosides and β-lactams.  
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β-lactams represent almost 50% of the total antibiotic consumption in Norway 
(NORM). This class of antibiotics includes penicillins, cephalosporins, monobactams and 
carbapenems. There are three different mechanisms that confer resistance to β-lactams; (I) 
target modification, (II) efflux and impermeability and (III) β-lactamases. β-lactamases are 
enzymes which hydrolyse the β-lactam ring and inactivate the β-lactam and is by far the most 
common resistance mechanism. The genes encoding β-lactamases can be located both on the 
chromosome and on plasmids. There are different schemes for classification of β-lactamases, 
and Giske et al introduced in 2008 a redefined classification system; where the β-lactamases 
were grouped into ESBLA, ESBLM-C, ESBLM-D, ESBLCARBA-A and ESBLCARBA-B(19). 
 
ESBLA was previously designated as ESBL, and are generally plasmid-mediated. 
ESBLA enzymes confer reduced susceptibility to penicillins, 1
st-4th generation cephalosporins 
and monobactams, but not to carbapenems. These enzymes are inhibited by β-lactamase 
inhibitors such as clavulanic acid. The β-lactamase genes encoding ESBLA include CTX-M, 
TEM, SHV, VEB and PER, with CTX-M being the most prevalent(34).  
 
 
1.6 Bacterial species investigated 
As shown in Figure 10 Escherichia coli (30.2%) and other Enterobacteriaceae (15.7%) 
account for the vast majority of aerobic Gram-negative species in Norwegian blood cultures. 
Klebsiella spp. (8.6%) is the dominating species among the other Enterobacteriaceae(6). 
 
E. coli are facultative anaerobe Gram-negative rods, which are motile and may appear 
with or without capsule(32). The normal habitat for E. coli is the gut of man and animals, but 
it may also colonize the lower end of urethra and vagina. Infection and spread of E. coli is by 
contact and ingestion (fecal-oral route), and may also be food-associated. Diseases caused by 
E. coli include urinary tract infections, diarrhoeal diseases, neonatal meningitis and 
septicaemia.     
 
Klebsiella spp. are also Gram-negative rods. They are often capsulated and are capable 
of aerobic and anaerobic respiration(32). The normal habitat for Klebsiella spp. is the gut of 
man and animals and moist inanimate environments, especially soil and water. Infection may 
be endogenous or acquired by contact spread. Unlike E. coli, Klebsiella spp. are rarely 
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associated with infection except as opportunistic pathogens in compromised patients. 
Klebsiella pneumoniae is the dominating species among Klebsiella spp.  
Pseudomonas aeruginosa are aerobic Gram-negative rods, which are motile and do 
not ferment carbohydrates. This pathogen is widespread in moist areas in the environment, 
and patients usually become infected by contact spread, directly or indirectly from these 
environmental sites(32). It is an important opportunistic pathogen in immunocompromised 
patients and can infect almost any body site given the right predisposing conditions. It may 
cause infections of skins and burns, is a major pathogen in cystic fibrosis, and can cause 
pneumonia in intubated patients. P. aeruginosa may also cause urinary tract infections, 







Figure 10. Distribution of all blood culture isolates (left) and blood culture isolates excluding common skin 
contaminants (right) from all Norwegian medical microbiology laboratories except one in 2009(6).  
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2. Aims of the study 
According to the Norwegian surveillance programme for antimicrobial resistance in 
human pathogens (NORM 2009)(6), aminoglycosides represent only 0.4% of the total 
antimicrobial consumption in Norway. Nevertheless, aminoglycosides are important 
antimicrobials and are often the first choice for empirical treatment of septicaemia with 
unknown cause. 
 
The prevalence of intermediate resistance and resistance to gentamicin in E. coli blood 
culture isolates in Norway is low, where 3.6% of blood culture isolates were reported as 
resistant in 2009. The numbers have nevertheless shown an increase during the years from 
2000-2009(6) (Figure 11). In Klebsiella spp., 1.2% of blood culture isolates were resistant in 
2009. The percentage of resistance was lower in urinary tract isolates than in blood culture 
isolates. In E. coli 2.1% of urinary tract isolates were resistant, while 0.6% of Klebsiella spp. 
isolates were resistant to gentamicin. In 2009, tobramycin was added to the surveillance 
scheme to further investigate aminoglycoside resistance. The level of resistance to tobramycin 
in E. coli blood culture isolates and urinary tract isolates were 2.4% and 1.5%, while the level 
of tobramycin resistant Klebsiella spp. were  1.4% and 0.3%, respectively (Table 4). 
 
 




Table 4. Proportion of E. coli and Klebsiella spp. isolates from blood culture and urine resistant to 
gentamicin and tobramycin in NORM 2009(6). 
Species Material Aminoglycoside % Resistant 
E. coli Blood (n=1379) Gentamicin 3.6 
  Tobramycin 2.4 
 Urine (n=1126) Gentamicin 2.1 
  Tobramycin 1.5 
Klebsiella spp.1 Blood (n=568) Gentamicin 1.2 
  Tobramycin 1.4 
 Urine (n=1004) Gentamicin 0.6 
  Tobramycin 0.3 
1 Klebsiella spp. includes Klebsiella pneumoniae and Klebsiella oxytoca 
 
 
The European Antimicrobial Resistance Surveillance System (EARS-Net) annual 
report for 2009(4) shows that the highest percentages of aminoglycoside resistance in invasive 
E. coli isolates are reported from the Southern and Eastern part of Europe, where most 
countries reported ~10% aminoglycoside resistance (Figure 12). During the last four years 
aminoglycoside resistance in E. coli has shown a significant increase in ten countries. This is 
consistent with the increase of all other resistance proportions for E. coli.  
 
Countries in the Eastern part of Europe have reported between 25-50% 
aminoglycoside resistance in invasive Klebsiella pneumoniae, and three countries in this area 
reported aminoglycoside resistance above 50% (Figure 12). In the period of 2006-2009 a 














Figure 12. Proportion of invasive isolates of E. coli (left) and Klebsiella pneumoniae (right) in Europe with 
resistance to aminoglycosides in 2009 (EARS-NET)(4). 
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The aims of this study include: 
 
Ø  Analysis of the susceptibility pattern of different aminoglycosides in clinically 
important Gram-negative isolates from Norway. 
 
Ø  Evaluation of the prevalence of genes encoding clinically important aminoglycoside 
modifying enzymes (AMEs). 
 
Ø  Evaluation of the prevalence of 16S rRNA methylase genes conferring high level 
broad-spectrum aminoglycoside resistance. 
 






















3. Materials and methods 
 
3.1 Strain collections 
Two collections of E. coli and Klebsiella spp. were extracted from the Norwegian 
surveillance programme for antimicrobial resistance (NORM) year 2007-2009(2,5,6) as 
described below. Additionally a collection of P. aeruginosa was selected from isolates 
received at the Reference centre for detection of antimicrobial resistance (K-res). 
 
3.1.1 Collection 1: E. coli and Klebsiella spp. from NORM 2009 
A total of 2510 isolates of E. coli (blood n = 1381 and urine n = 1129) and 1578 
isolates of Klebsiella spp. (blood n = 571 and urine n = 1007) were included in NORM 2009 
(Table 5).  
 
Table 5. The total number of E. coli and Klebsiella spp. included in NORM 2009 (collection 1), and 
distribution of isolates with reduced susceptibility to gentamicin and/or tobramycin. 





E. coli blood 1381 61 
E. coli urine 1129 44 
E. coli total 2510 105 
   
Klebsiella spp. blood 571 17 
Klebsiella spp. urine 1007 15 
Klebsiella spp. total 1578 32 
1 GEN=gentamicin, TOB=tobramycin 
 
Initial antimicrobial susceptibility testing was performed in each Norwegian 
laboratory contributing to NORM, using agar disk diffusion systems from Oxoid (Oxoid Ltd, 
Basingstoke, UK) or BD (Becton Dickinson, Cockeysville, MD, USA) in agreement with 
breakpoints from the Norwegian Working Group on Antibiotics (NWGA). Inhibition-zones 
detected by the disk-diffusion method from a broad panel of antibiotics, including the 
aminoglycosides gentamicin and tobramycin, were available in the NORM database 
(Appendix A; Table 1-2). 
 
Using the breakpoints from the BD and Oxoid distributers (Table 6), a total of 137 isolates 
with reduced susceptibility to gentamicin and/or tobramycin (Table 5) were selected for 
further studies. 
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Table 6. Breakpoints for gentamicin and tobramycin from the BD and Oxoid distributers. 
Distributor Susceptible (S) Intermediate (I) Resistant (R) 
BD > 19 mm 17-18 mm < 16 mm 




3.1.2 Collection 2: ESBLA-positive E. coli and Klebsiella spp. from NORM 
2007-08  
A total of 68 PCR-confirmed ESBLA-positive isolates, representing 60 E. coli (blood n 
= 32 and urine n = 28) and 8 Klebsiella spp. (all blood) isolates were identified in NORM 
2007(2) and 2008(5). The different ESBLA-types detected are listed in Table 7. 
 
 
Table 7. Distribution of the ESBLA-types included in collection 2. 
 ESBLA- type 
Species CTX-M gr.1 CTX-M gr. 9 SHV 
E. coli (n = 60) 30 26 4 
Klebsiella spp (n = 8) 3  5 
 
 
3.1.3 Collection 3: Carbapenem non-susceptible P. aeruginosa from K-res 
2007-09 
Between 2007 and 2009 K-res received a total of 121 P. aeruginosa isolates with 
reduced susceptibility to carbapenems (imipenem and/or meropenem).  Forty-four of these 
isolates were isolated from cystic fibrosis patients, and not included in this study. The 










3.2 Phenotypic methods  
3.2.1 Preparation of stock cultures 
Stock cultures were prepared of all the clinical isolates examined in this study using 
glycerol as the osmotic protector. 
 
Procedure: 
1. Upon arrival at K-res, the isolates in collection 1 were cultured on green agar plates, 
while the isolates in collection 2 and 3 were cultured on green agar plates containing 
100 mg/ml ampicillin (Appendix A; Table 8).  
2. After overnight incubation at 35ºC, 8 to 10 colonies from the culture were transferred 
to 1 ml freeze broth (Appendix A; Table 8) 
3. The broth were homogenized on a vortex mixer and stored at -70ºC. 




3.2.2 VITEK2 identification and susceptibility testing 
VITEK2 (bioMérieux, Marcy l’Etoile, France) is a fully automated systems for bacterial 
identification and susceptibility testing using fluorescence-based technology. Species 
identification of all three strain collections in this study was performed using the IDGN card 
(bioMérieux) of VITEK2 (bioMérieux) according to the manufacturers instructions. The 
VITEK2 Gram-negative susceptibility card AST029 (bioMérieux) evaluate a broad panel of 
antibiotic classes including: Gentamicin, tobramicin, ampicillin, cefotaxime, cefoxitin, 
cefpirome, cefpodoxime, ceftazidime, cefuroxime, ciprofloxacin, mecillinam, meropenem, 
nitrofurantoin, trimethoprim, trimethoprim/sulphamethoxazole, amoxicillin/clavulanic acid, 
piperacillin/tazobactam, aztreonam, cefalotin, cefuroxime axetil, and nalidixic acid. VITEK2 
AST was performed on all three strain collections to evaluate level of resistance to other 








1. Colonies from an overnight culture grown on green agar plates (collection 1) or green 
agar plates containing 100 mg/ml ampicillin (collection 2 and 3) were suspended in 3 
ml 0.45% NaCl (Appendix A; Table 8), and the turbidity was measured by a 
densitometer and adjusted to 0.52-0.63 McFarland. 
2. The tube with the bacterial suspension was placed in a rack together with 
identification card IDGN and the anti susceptibility card AST029, respectively and 
scanned for registration. 
3. The rack was placed in the VITEK2 where each test card was automatically filled 
with the bacterial suspension and automatic identification and susceptibility testing 
was performed by kinetic fluorescence measurement every 15 min.  
4. The software then analysed the data and reported the results. 
 
 
3.2.3. Oxydase test 
The oxydase test is used to determine if a bacterium produces cytochrom c oxydase 
which can utilize oxygen for energy production with an electron transfer chain. The reagent 
will act as electron donor and when the reagent is oxidased, a dark blue colour will appear. 
Pseudomonadaceae produce cytochrom c oxydases and are oxydase positive bacteria. 
Enterobacteriaceae do not produce cytochrom c oxydases, and are oxydase negative (Ref. Mc 




1. One drop of oxydase reagent (Appendix A; Table 8) was transferred to filter paper. 
2. One colony from a fresh culture of the isolate was added to the oxydase reagent on the 
filter paper. 







3.2.4 EUCAST Disk Diffusion  
During 2009-2010 The European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) developed a disk diffusion test for routine antimicrobial susceptibility testing. The 
method is derived from the Kirby-Bauer method(11). Disk diffusion is a semi quantitative 
method used to examine microbes’ susceptibility to specific antibiotics. It allows 
categorization of bacterial isolates as susceptible, intermediate or resistant to a variety of 
antimicrobial agents (www.eucast.org Access date: 120311). A micro-organism is defined as 
susceptible (S) by a level of antimicrobial activity associated with a high likelihood of 
therapeutic success. It is defined as intermediate (I) by a level of antimicrobial agent activity 
associated with uncertain therapeutic effect. And finally, a micro-organism is defined as 
resistant (R) by a level of antimicrobial activity associated with a high likelihood of 
therapeutic failure. Clinical breakpoints for relevant antimicrobials are established for 
everyday use in the clinical laboratory to advise on patient therapy.  
 
Commercially prepared filter paper disks impregnated with a standard concentration of 
the antimicrobial agents are applied to the surface of an agar medium inoculated with the test 
organism. The antibiotic will diffuse into the agar, creating a high concentration close to the 
antibiotic disk and continuous lower concentrations with increasing distance to the disk. 
Following incubation, a bacterial lawn appears on the plate and zones of inhibition of 
bacterial growth appear around the antibiotic disk (Figure 13). The test is performed under 
standardized conditions and hence the size of the inhibition zone is dependent of the degree of 
sensitivity of the microorganism to the antibiotic(30). 
 
In this study, susceptibility testing against the following aminoglycosides was 
performed on collection 1 and 2: amikacin 30 µg (Oxoid), gentamicin 10 µg (Oxoid), 
kanamycin 30 µg (Oxoid), netilmicin 10 µg (Oxoid), streptomycin 10 µg (Oxoid), tobramycin 
10 µg (Oxoid), arbekacin 30 µg (BD), and isepamicin 30 µg (BD).  Susceptibility testing 
against amikacin 30 µg (Oxoid), gentamicin 10 µg (Oxoid), netilmicin 10 µg (Oxoid), 







1. A 0.5 McFarland suspension of the organism were made from an overnight culture 
grown on green agar plates (collection 1) or green agar plates containing 100 mg/ml 
ampicillin (collection 2 and 3) in 0.85% NaCl, and swabbed on a Mueller-Hinton 
(MH) II-plate (BD), (Appendix A; Table 8). 
2. A panel of aminoglycoside disks were applied to the plate within 15-60 minutes. 
3. The plates were incubated at 35ºC in ambient air for 18 ± 2 hours. 
4. After incubation the inhibition-zones were measured using a slide calliper and 
recorded. 
5. E. coli ATCC 25922 was used as reference strain in investigation of collection 1 and 




Figure 13. EUCAST disk diffusion showing a MH II-plate with six different aminoglycoside disks. 




3.2.5 Etest susceptibility testing 
Etest is a quantitative technique for determining the antimicrobial susceptibility of 
antimicrobial agents. An Etest is a thin plastic strip, containing a predefined, stable gradient of 
an antimicrobial agent which is calibrated to give stable gradient agar diffusion. After 
incubation, the position of the growth/inhibition edge for a particular bacterium/antimicrobial 
agent combination determine the minimal inhibitory concentration (MIC) of the agent 
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(http://www.abbiodisk.com/pdf/etm_html/03_etm.htm Access date: 18022011) (Figure 14). 
The MIC is the lowest concentration of the antimicrobial agent that results in inhibition of 
visible growth analogue with colonies on a plate or turbidity in broth culture(30). 
 
MIC`s were determined for the isolates in collection 1 and 2 using the following panel 
of aminoglycoside Etests (bioMérieux): amikacin, gentamicin, kanamycin, netilmicin, 
streptomycin, and tobramycin. In collection 3 the MICs were determined on the same panel of 
aminoglycosides, except kanamycin. 
 
Procedure:  
1. A 0.5 McFarland suspension of the organism were made from an overnight culture 
grown on green agar plates (collection 1) or green agar plates containing 100 mg/ml 
ampicillin (collection 2 and 3) in 0.85% NaCl, and swabbed on a MH-II plate (BD). 
2. The Etests were applied on the swabbed plates using the Etest applicator Simplex C76 
(bioMérieux). 
3. The plates were incubated at 35ºC in ambient air for 16-18 hours. 
4. After incubation, the MIC values were determined and recorded. 
5. E. coli ATCC 25922 was used as reference strain in investigation of collection 1 and 




Figure 14. Etest susceptibility test showing a MH-II plate with six different aminoglycoside Etests. 




3.3 Molecular methods  
3.3.1 Isolation of DNA from bacteria 
DNA from all the isolates of the three collections was isolated using the QIAgen 
GenoM-48 biorobot (QIAgen, Hilden, Germany) according to the manufacturer’s instructions. 
In brief, DNA from lysed bacteria binds to the surface of magnetic particles. Several washing 
steps are performed, to improve the purity of the DNA. DNA is finally eluted in water(8). 
 
Procedure:  
1. 200 µl of a 0.5 McFarland suspension of the organism in 0.85% NaCl was prepared 
from an overnight culture and transferred to sample tubes. 
2. The sample tubes were placed in the robot which performed all steps of the isolation, 
including sample lysis, binding to the GenoPrep beads, washing steps and elution with 
reagents from MagAttract DNA Mini M48 Kit (QIAgen). 
3. Following the isolation, the DNA was stored at 2 - 8ºC. 
 
 
3.3.2 Polymerase Chain Reaction (PCR) 
Polymerase chain reaction (PCR) is a rapid method for amplification of DNA in vitro. 
Target DNA is heated to separate the strands (denaturation), and DNA oligonucleotide 
complementary to the target DNA sequence, is added together with a heat-stable enzyme 
DNA polymerase. As the reaction cool down, the primers will bind to the target strands 
(annealing). DNA polymerase then extends the primers using the target strands as templates 
(elongation). After an incubation period, the mixture is again heated to separate the newly 
made strands, and the process is repeated. After 20-30 cycles, a 106-109–fold increase in the 
target sequence is obtained (Figure 15). Agarose gels are used for detection of the amplified 
PCR-products at the end-point of the PCR-reaction (see below). 
 
In this study, hot-start PCRs were performed by using JumpStart REDTaq ReadyMix 
PCR Reaction Mix (Sigma Aldrich, St. Louis, USA) according to the manufacturer’s 




Figure 15. The different steps of PCR, including denaturation of the dsDNA, annealing of primers, and 




General procedure for all PCRs: 
1. For each reaction: 3 µl DNA was added to 22 µl PCR mastermix (Appendix A; Table 
3,4-6).  
2. Controls included, in addition to ddH2O as a mastermix control, are listed in Table 8.  
3. The PCR was run on a PCR thermocycler (Applied Biosystems, Foster City, Ca) 











Table 8. Positive and negative PCR-controls used in this study. 
PCR Positive control Negative control Reference 
16S rDNA Enterococcus faecalis 
ATCC 29212 




aac(6’)-Ib E. coli A3-21  E. coli ATCC 25922   L. Poirel. Personal communication 




ant(2’’)-Ia P. aeruginosa K44-24  E. coli ATCC 25922   (39) 
ant(4’)-IIb P. aeruginosa K44-36  E. coli ATCC 25922   This study 
rmtA Plasmid ATCC 25922  E. coli Arakawa Y. Personal communication 
rmtB A4-26 ATCC 25922  E. coli (10) 
rmtC NA1 ATCC 25922  E. coli  
rmtD NA1 ATCC 25922  E. coli  
rmtE NA1 ATCC 25922  E. coli  
armA A4-25 ATCC 25922  E. coli (10) 
npmA A4-47 ATCC 25922  E. coli Arakawa Y. Personal communication 
1 NA; not available, 2 ATCC: American Type Culture Collection 
 
 
3.3.3 Agarose gel electrophoresis 
Agarose gel electrophoresis is a simple, rapid and highly sensitive method widely used 
to separate DNA and RNA molecules by size(28). The rates of which DNA/RNA- molecules 
migrate are inversely proportional to their molecular weight. Thus agarose gel electrophoresis 
may also be used to estimate the size of DNA or RNA molecules by comparing with the 
migration of molecules of known size (molecular ladders). Nucleic acid molecules are 
negatively charged, and will migrate in electric fields towards the positive electrode. The 
agarose molecules will delay the migration of larger molecules and smaller molecules will 
therefore move faster. As a result, molecules of different sizes will be separated in the gel. 
 
Procedure: 
1. 1% agarose (Seakem LE agarose, Lonza, Rochland, ME, USA) was dissolved in 
0.75X Tris/Borate/EDTA-buffer (TBE) (Appendix A; Table 8) by boiling the solution 
in a microwave oven. 
2. 0.5 µg/ml ethidium bromide (EtBr) (Sigma-Aldrich) was added for staining of the 
DNA molecules 
3. The agarose-EtBr solution was poured into a geltray fitting the electrophoresis 
apparatus (BioRad laboratories, Hemel Hemstead, UK), containing the combs, and 
allowed to set for about 30 minutes 
4. 3 µl of each PCR product was loaded into the gel wells. 
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5. 4 µl of 1 Kb+ DNA molecular size marker (Invitrogen, Carlsbad, CA, USA) 
(Appendix A; Figure 1) was loaded into the flanking wells. 
6. The electrophoresis was run at 100 V for approximately 1 hour. 
7. The DNA bands were visualized using the GelDoc system (BioRad). 
 
 
3.3.4 PCR-based detection of 16S rDNA 
The quality of the DNA extraction from the isolates in the three strain collections were 
all tested by 16S rDNA PCR. Strong 16S rDNA-PCR products indicate high quality of the 
DNA templates, while unsuccessful amplification of 16S rDNA reflects poor isolation of 
DNA, DNA degradation, or the presence of PCR inhibitors. Modified universal primers 
giving PCR-products of about 1500 bp, described by Weisburg et al., 1991, were used. 
(Appendix A, Table 6) 
 
 
3.3.5 PCR-based detection of aminoglycoside modifying enzymes (AMEs) 
Strain collection 1 and 2 were screened for the following AMEs: aac(6')-Ib, aac(3)-II, 




3.3.6 PCR-based detection of 16S rRNA methylases 
Eight isolates from collection 1 and one isolate from collection 2, all resistant or 
intermediate resistant to amikacin, gentamicin, tobramycin, kanamycin, and netilmicin were 
screened for the following 16S rRNA methylases: rmtA, rmtB, rmtC, rmtD, rmtE, armA, and 
npmA. Primers, conditions and mastermix are described in Appendix A, Table 3-6. Sixteen 
isolates from collection 3 with resistance to amikacin, gentamicin, tobramycin, and netilmicin 






3.3.7 DNA sequencing reaction 
The Sanger method is the most widely used method for determination of the precise 
nucleotide sequence of a DNA fragment(40). Briefly, the method is based on DNA synthesis 
in the presence of fluorescent labelled dideoxynucleotides (ddNTP), which differ from normal 
deoxynucleotides (dNTP) in that they lack a 3’-hydroxyl group (OH). A mix of dNTP and a 
small portion of the ddNTP are used. DNA synthesis proceeds normally until DNA 
polymerase inserts a ddNTP instead of a normal dNTP. When a ddNTP is added to the 
growing DNA strand, it terminates the chain elongation because there is no 3’-OH for the 
next nucleotide to be attached. In this manner various truncated chain lengths will be 
produced. Automated fluorescence detection machines will detect and record the fluorescence 
and the nucleotide order can be determined. 
 
Before starting the sequencing reaction, it is important to remove access dNTP and 
DNA polymerase from the PCR-product. Two hydrolytic enzymes; Shrimp Alkaline 
Phosphatase (SAP) and Exonuclease I (Exo) will remove dNTPs and DNA polymerase, 
respectively and purify the PCR-product. 
 
Sequencing in this study was performed using the BigDye v. 3.1 sequencing chemistry 
(Applied Biosystems). To confirm the PCR-results, 14 of the positive aac(6’)-Ib isolates and 
eight of the positive aac(3)-II isolates were sequenced. In addition the positive PCR-products 
from the ant(2’’)-Ia-, rmtB-, and rmtD-PCR were sequenced. The primers used in the 
sequencing reaction, was the same as for the PCRs. 
 
Procedure: 
A. Purification of the PCR-product. 
1. 1 µl of Exo-SAP (USB, Cleveland, Ohio) was added to each PCR-product and the 
tubes were put into the PCR thermocycler (Applied Biosystems). 
2. Cycling-programme 
  37°C   1 min               
37°C   90 min    
85°C   15 min  
   4°C      ∞ 





B. Sequencing PCR and analyses: 
1. For each reaction, 1 µl template was added to 19 µl sequencing mastermix (Appendix 
A; Table 7).  
2. The PCR thermocycler (Applied Biosystems) was programmed and according to 
program given in Appendix A; Table 5. 
3. Nucleotide sequencing was performed at the Sequencing core facility at the 
University of Tromsø using ABI Prism 3130XL Genetic Analyser (Applied 
Biosystems) 
4. Editing and alignment of the DNA sequences were performed using the SeqMan II 
software package (DNAStar Inc., Madison, WI, USA).  
5. Searcing for nucleotide sequence homology was performed using BLAST available at 




3.4 Pulsed-field gel electrophoresis (PFGE) 
Pulsed-field gel electrophoresis (PFGE) is a method for resolving chromosomal DNA 
and is a well established molecular strain typing method. PFGE may be used for genotyping 
or genetic fingerprinting and has been  considered a gold standard in epidemiological studies 
of pathogenic organisms. This method allows separation of whole genomes after enzymatic 
digestion by electrophoresis. DNA fragments from 100 bp to 10 Mbp can be separated.  
 
Bacterial cells are moulded into agarose plugs, to protect the chromosome from 
fragmentation. The cells are then lysed by enzymes such as lysozyme. After washing-
procedures, the plugs are treated with proteinase K, to inactivate nucleases that otherwise will 
degrade the DNA. The DNA in the agarose plugs are then digested with restriction enzymes 
that have relatively few recognition sites, resulting in a relatively small number of restriction 
fragments. The fragments are then separated in an agarose gel using electrical fields of 






Eighteen representative aac(3)-II-positive E. coli isolates with elevated gentamicin 
resistance from collection 1 from all over Norway were investigated by PFGE to investigate if 
they were part of a successful Norwegian clone. The isolates included in the PFGE are listed 





Table 9. aac(3)-II positive E. coli isolates with elevated gentamicin resistance investigated by PFGE. Green 
= susceptible, yellow = intermediate resistant, and red = resistant. 
     Etest MIC µg/ml 










K64-13 E. coli Blood Aker 3 64 12 8 6 
K64-17 E. coli Blood Bærum 1,5 128 16 12 16 
K64-18 E. coli Blood Bærum 2 96 12 8 8 
K64-22 E. coli Blood Drammen 3 96 8(8) 8 8 
K64-43 E. coli Blood Haukeland 4 96 8 16 8 
K64-44 E. coli Blood Haukeland 3 128 12 24 12 
K64-46 E. coli Blood Haukeland 3 96 12 24 12 
K64-49 E. coli Urine Haukeland 3 96 12 12 12 
K64-55 E. coli Blood Kristiansand 3 96 8 8 12 
K64-70 E. coli Blood Molde 3 128 12 12 12 
K65-03 E. coli Blood Stavanger 3 96 12 12 8 
K65-06 E. coli Urine Stavanger 3 128 16 12 8 
K65-08 E. coli Urine Stavanger 2 96 12 12 12 
K65-21 E. coli Blood Tromsø 3 96 16 8 12 
K65-25 E. coli Urine Tromsø 3 96 12 12 8 
K65-34 E. coli Urine Trondheim 3 96 16 12 16 
K65-44 E. coli Blood Ullevål 3 128 12 12 12 
K65-52 E. coli Urine Ullevål 3 96 16 12 16 






In addition, PFGE was performed on 18 E. coli isolates from collection 1 were the 
Etest and the disk diffusion results for tobramycin did not correspond. Due to a change in 
EUCAST breakpoints after the analysis was performed, some of Etest/disk diffusion results 









Table 10. E. coli isolates with not corresponding tobramycin resistance investigated by PFGE, with their 
tobramycin MIC profiles, mm-zones, aac(6’)-Ib, and aac(3)-II PCR results. Green = susceptible, yellow = 
intermediate resistant and red = resistant 
    TOB1 AME 
Ref. no Species Material Location Etest Disk aac(6')-Ib aac(3)-II 
K64-01 E. coli Blood AHUS2 6 16 neg pos  
K64-03 E. coli Urine AHUS2 12 12 neg pos 
K64-23 E. coli Blood Drammen 8 13 neg pos 
K64-32 E. coli Blood Fredrikstad 12 14 neg pos 
K64-33 E. coli Blood Fredrikstad 8 12 neg pos 
K64-39 E. coli Blood Haukeland 6 12 neg pos 
K64-43 E. coli Blood Haukeland 8 12 neg pos 
K64-53 E. coli Blood Kristiansand 6 14 neg pos 
K64-54 E. coli Blood Kristiansand 6 15 neg pos 
K64-66 E. coli Urine Lillehammer 8 14 neg pos 
K64-67 E. coli Urine Lillehammer 4 17 neg pos 
K65-01  E. coli Blood Stavanger 6 15 neg neg 
K65-03 E. coli Blood Stavanger 12 12 neg pos 
K65-23 E. coli Blood Tromsø 8 14 neg pos  
K65-28 E. coli Blood Trondheim 8 14 pos pos 
K65-45 E. coli Blood Ullevål 8 12 neg pos 
K65-46 E. coli Blood Ullevål 8 14 neg pos 
K65-47 E. coli Blood Ullevål 6 14 neg pos 
1 TOB=tobramycin, 2 AHUS= Akershus university hospital 
 
Procedure: 
A. Preparation of PFGE plugs 
1. One bacterial colony from a fresh agar culture was transferred into 5 ml of BHI-
medium (Appendix A; Table 8) and incubated overnight at 37°C, using shaking to 
increase the access of O2. 
2. 50 µl of the culture were transferred into to a new tube of 5 ml of BHI and incubated 
for 4 hours at 37°C, using shaking. When harvested after 4 hours, the bacterial cells 
should be in exponential growth. 
3. The cells were centrifuged at 3500 rpm for 10 min. 
4. The supernatant was removed and the bacterial cells were resuspended in 1 ml of cold 
PIV-buffer (Appendix A; Table 8). 
5. 495 µl of the suspension were transferred to an eppendorf tube, and 5 µl lysozym 
(100mg/ml) (Sigma-Aldrich) were added. The cells were mixed well by vortexing, and 
equilibrated at 50°C in a water bath. 
6. 500 µl 2% Megabase agarose (BioRad) dissolved in PIV-buffer and equilibrated at 
50°C, were added to the bacterial suspension and mixed thoroughly. The mixture was 
transferred to the plug mould, and the plugs were left to solidify at 4°C for 15 min. 
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7. The solidified plugs were transferred to new tubes, and 2 ml of lysis buffer (Appendix 
A; Table 8) were added and incubated at 37°C for 2 hours, using slow shaking. 
8. The lysis buffer was removed, and the plugs were washed in 1 ml ddH2O for 15 min. 
9. After removing ddH2O, 1 ml of ESP buffer (Appendix A; Table 8) containing 50 µl/ml 
proteinase K-solution (20 mg/ml, VWR, West Chester, PA, USA) were added and 
incubated at 50°C in a water bath over night. 
10. The ESP-solution was removed and the plugs were washed 3 x 30 min in 1 ml TE-
buffer (Appendix A; Table 8). 
11. The plugs were stored in TE-buffer at 4°C. 
 
B. Restriction enzyme digestion of DNA in agarose plugs 
1. A thin slice of the plug was cut and transferred to an eppendorf tube. 
2. The plug was washed 3 x 30 min in 500 µl restriction enzyme buffer (Buffer 4, New 
England BioLabs, Ipswitch, Ma, USA) containing bovine serum albumin (BSA) 
(Appendix A; Table 8). 
3. The restriction enzyme mix, 20 U XbaI (New England BioLabs) per 125 µl total 
enzyme mix, was prepared (Appendix A; Table 8). 
4. The plugs was transferred to 125 µl restriction enzyme mix and incubated at 37°C 
over night. 
5. The plug was washed 3 x 30 min in TE buffer. 
 
C. Gel electrophoresis 
1. 1% agarose (Seakem LE agarose) was dissolved in 0.5X TBE by boiling the solution 
in a microwave oven and equilibrated to 50°C in a waterbath. 
2. The gel equipment was prepared, and the plugs were placed onto the gel comb and 
mounted directly into the gel by inserting the comb before the agarose was poured. A 
low range PFG marker (New England Biolabs) was included (Appendix A, Figure 2). 
The gel was left to solidify for 30 min at room temperature. 
3. The electrophoresis chamber was filled with 1.8-2 l of 0.5X TBE, and the circulation 
was started to cool the system to 12°C. 
4. The comb was released from the gel, and access gel was removed. 
5. The gel was placed in the electrophoresis chamber, the program parameters were set, 




Pulstime:   1-20 sec 
Total runtime:  21 hours 
Voltage:     6.0V/cm= 200V 
Angle:   120° 
Temperature:  12°C 
Gel running buffer: 0.5 x TBE 
6. After the electrophoresis, the gel was stained in an EtBr-solution (Appendix A; Table 
8) for 20 min and de-stained in dH2O for 40 minutes.  
7. The DNA bands were visualized using the GelDoc system (BioRad, USA).  
8. Interpretation of DNA relatedness was computationally analysed in BioNumerics 
v.6.01 (Applied Maths, Sint-Martens-Latens, Belgium) using the band-based DICE 
similarity coefficient and the unweighted pairs geometric matched analysis (UPGMA) 
with a position tolerance of 1% and 1% for band comparison. 
 
 
3.5 Plasmid transfer studies 
Many plasmids containing antibiotic resistance determinants have the ability to move 
between bacterial cells by conjugation. In Gram-negative bacteria, conjugation involves cell 
to cell contact via sex-pili. In this study, 12 isolates showed an aminoglycoside resistance 
profile but were negative for the aminoglycoside modifying enzymes tested for, nine isolates 
in collection 1 (E. coli n = 6 and Klebsiella spp. n = 3) and three E. coli isolates from 
collection 2. Four of these isolates were chosen for further plasmid transfer studies to explore 
if the resistance marker were located on a transferable plasmid. The resistance profile of the 
donor isolates are shown in Table 11. A rifampicin resistant, aminoglycoside susceptible E. 












Table 11. The donor isolates included in the plasmid transfer studies, including their MIC profile. 
    Etest MIC µg/ml 










K64-71 E. coli Blood Molde 3 32 64 6 32 
K65-38 E. coli Blood Tønsberg 2 16 32 4 16 
K64-31 E. coli Blood Fredrikstad 2 24 4 4 2 
K65-35 K. pneumoniae Urine Trondheim 2 16 1,5 3 2 




1. The donor and recipient strains were inoculated in LB-medium (Appendix A; Table 8) 
and incubated over night at 37°C with shaking. 
2. The overnight cultures were diluted 1:100 in LB-medium and incubated at 37°C with 
shaking until the cultures were in exponential growth (OD600 = 0.3-0.5). OD was 
measured on a SprectraMax Plus (Molecular Devices, Sunnyvale, CA, USA). 
3. The donor and recipient cultures were mixed in two different ratios: 
1:1 (2.5 ml donor and 2.5 ml recipient) 
1:9 (0.5 ml donor and 4.5 ml recipient) 
 The mixed cultures were incubated for 2 hours at 37°C, with very slow shaking. 
4. The transconjugants were diluted 100, 10-2 and 10-4 and 100 µl of the dilutions were 
spread on LB-plates containing rifampicin (100 µg/ml) and gentamicin (6 µg/ml) 
(Appendix A; Table 8). The donor and recipient cells were diluted 10-5 and 100 µl of 
the dilutions were spread on LB-plates containing gentamicin and LB-plates 
containing rifampicin, respectively (Appendix A; Table 8). All plates were incubated 
at 37°C overnight. 
5. The next day, possible transconjugants, recipients and donors were counted and the 
conjugation frequencies were calculated. 
6. From each donor, five possible transconjugants were spread on green agar plates, and 
incubated at 37°C overnight. 





3.6 Multilocus sequence typing (MLST) 
Multilocus sequence typing (MLST) is a widely used typing method to determine the 
clonality of strains. This technique makes use of multiple housekeeping gene loci to 
characterise bacterial species. The loci sequences are given allelic numbers and the 
combination of seven housekeeping gene loci defines a sequence type (ST).  
 
MLST schemes have been developed for different organisms, and in this study MLST 
schemes for E. coli and P. aeruginosa have been used. For E. coli, the housekeeping genes 
adk, fumC, gyrB, icd, mdh, purA, and recA have been sequenced. The housekeeping genes 
acsA, aroE, guaA, mutL, nuoD, ppsA, and trpE belong to the MLST scheme to determine the 
sequence types of P. aeruginosa. The collection of MLST data on E. coli is available online 
on http://mlst.ucc.ie/mlst/dbs/Ecoli/ and the P. aeruginosa collection are available on 
http://pubmlst.org/paeruginosa/.  
 
PCR and sequencing of the housekeeping genes belonging to the different MLST 
schemes were performed according to the procedure previously described in this chapter. The 
different mastermix and PCR-conditions are described in Appendix A; Table 5-7. Sequence 
analyses were performed using SeqMan DNAStar Lasergene 8.1.3 (DNAStar Inc., Madison, 
WI). Sequences for each housekeeping gene were submitted to the online MLST databases for 
determination of allele number and sequence type.  
 
In this study MLST was performed on the isolates harbouring 16S rRNA methylases, 
and partial MLST was performed on selected transconjugants to verify if the plasmid transfer 












3.7 Comparison of phenotypic methods 
The comparison between the different methods was performed on Etest versus disk 
diffusion, Etest versus VITEK2 anti susceptibility testing (AST) and VITEK2 AST versus 
disk diffusion. The aminoglycosides looked into were tobramycin, gentamicin and amikacin 
in all three strain collections. In this comparison, the Etest results were considered as the key 
in comparison with disk diffusion and VITEK2 AST. When comparing VITEK2 AST and 
disk diffusion, VITEK2 AST was considered as the key. Disk diffusion or VITEK2 AST is 
the standard method for detecting reduced susceptibility in Norwegian microbiology 
laboratories. When the disk diffusion or the VITEK2 AST considers a isolate susceptible and 
the Etest shows resistance, this is considered a very major error since the result from the disk 
diffusion or the VITEK2 AST will be reported.  
 
The comparisons of methods are classified as follows: 
Very major error: Disk diffusion/VITEK2 AST: S Etest: R 
Major error:  Disk diffusion/VITEK2 AST: R Etest: S 
Minor error:  Disk diffusion/VITEK2 AST: S Etest: I 
Minor error:  Disk diffusion/VITEK2 AST: I Etest: S 
Minor error:  Disk diffusion/VITEK2 AST: R Etest: I 
Minor error:  Disk diffusion/VITEK2 AST: I Etest: R 
 





4.1 Prevalence of aminoglycoside resistance 
 Antimicrobial susceptibility testing on several different aminoglycosides was 
performed on the three different strain collections using Etest and disk diffusion test. In 
addition, gentamicin and tobramycin MIC values from the automated VITEK2 AST system 
were included. The clinical breakpoints defined by EUCAST or CLSI (Appendix B; Table 1) 
were used. The results of the resistance pattern used for investigation of the prevalence are 
based on the Etest results. The results from both the Etest and disk diffusion test are listed in 
Appendix B; Table 2-15). Because of no available breakpoints for streptomycin, arbekacin 
and isepamicin the resistance profiles for these aminoglycosides have not been analysed. 
 
4.1.1 Collection 1: E. coli and Klebsiella spp. from NORM 2009  
When testing the 137 selected isolates from collection 1, 28 (20 %) isolates did not 
show reduced susceptibility by Etest as reported in NORM 2009. 19 isolates (18%) were E. 
coli and nine isolates (28%) were Klebsiella spp. The Etest resistance profiles of blood culture 
and urinary tract isolates of E. coli and Klebsiella spp tested from NORM 2009, respectively 
are shown in Figure 16. 
 
The results showed that the overall prevalence of reduced susceptibility to amikacin 
was low. In E. coli the level of reduced susceptibility to amikacin was 0.6% in blood culture 
isolates and 0.1% in urinary tract isolates. In Klebsiella spp. reduced susceptibility to 
amikacin was 0.4% in blood culture and 0.2% urinary tract isolates. The prevalence of 
reduced susceptibility to gentamicin were 3.8% and 2.5% in E. coli from blood culture and 
urinary tract isolates, respectively and 1.4% and 0.7% in Klebsiella spp. Regarding reduced 
susceptibility to tobramycin  in E. coli, the level was 4.1% in blood culture isolates and 2.6% 
in urinary tract isolates. In Klebsiella spp. the figures were 2.0% and 1.0%, respectively. The 
level of reduced susceptibility to netilmicin also showed higher values in E. coli compared to 
Klebsiella spp. In E. coli from blood culture isolates the prevalence of reduced susceptibility 





Figure 16. Level of reduced susceptibility to different aminoglycosides in collection 1, including the blood 




4.1.1.1 Broad-spectrum aminoglycoside resistance in collection 1 
 
With respect to broad-spectrum aminoglycoside resistance 1% of the isolates only 
showed reduced susceptibility to either gentamicin or kanamycin (Table 12). The prevalence 
of isolates with reduced susceptibility to both gentamicin and tobramycin was 1% in E. coli. 
No Klebsiella spp. isolates showed reduced susceptibility to both gentamicin and tobramycin 
(Table 12). A total of 46% of the isolates showed reduced susceptibility to gentamicin, 
tobramycin, netilmicin, and kanamycin. And finally, when also including amikacin altogether 
5% of the isolates showed reduced susceptibility to all aminoglycosides investigated. The 
distribution of reduced susceptibility to several aminoglycoside in collection 1, including 
results for E. coli and Klebsiella spp. separately, are shown in Figure 17.  
 




n = 109 
E. coli (%) 
n = 86 
Klebsiella spp. (%) 
n = 23 
KAN 1 (1) 0 1 (4) 
GEN 1 (1) 0 1 (4) 
GEN  + TOB 1 (1) 1 (1) 0 
GEN + TOB + KAN 2 (2) 2 (2) 0 
TOB + NET + KAN 6 (5) 2 (2) 4 (18) 
GEN + TOB + NET 35 (33) 25(29) 10 (44) 
GEN + TOB + NET + KAN 50 (46) 47 (55) 3 (13) 
AMK + TOB + NET + KAN 7 (6) 4 (5) 3 (13) 
AMK + GEN + TOB + NET + KAN 6 (5) 5 (6) 1 (4) 































The prevalence of reduced susceptibility to gentamicin, tobramycin and netilmicin 
combined were observed in 29% of the E. coli isolates and 44% of the Klebsiella spp. isolates. 
Finally, the prevalence of reduced susceptibility to all aminoglycosides tested, including 




Figure 17. Distribution of broad-spectred aminoglycoside resistance in collection 1, including results for  





4.1.1.2 Co-resistance to other classes of antibiotics 
The results from the VITEK2 Gram-negative card AST029 were used to evaluate the 
level of resistance to other classes of antibiotics. A total of 36 (34%) of the isolates in 
collection 1 with reduced susceptibility to different aminoglycosides showed a phenotypic 
ESBLA or ESBLM-C profile while 58 (54%) were resistant to ciprofloxacin and 86 (80%) were 
resistant to trimethoprim/sulfamethoxazole. Two isolates were resistant to meropenem, and 
these isolates had previously been analysed at K-res. They turned out to be Klebsiella 
pneumoniae carbapenemase (KPC)-positive isolates, isolated from the same patient in two 
different hospitals(37). Twenty-one (20%) isolates had a phenotypic ESBLA or ESBLM-C 
profile, together with reduced susceptibility to aminoglycosides and resistance to 














G + T 
G + T + K 
T + N + K 
G + T + N 
G + T + N + K 
A + T + N + K 
A + G + T + N + K 
Klebsiella spp. 
 57 
4.1.2 Collection 2: ESBLA-positive E. coli and Klebsiella spp. NORM 2007-
08 
The Etest resistance profiles of the total number of isolates tested from collection 2 are 
listed in Table 13. The prevalence of reduced susceptibility to amikacin was 7% in collection 
2. No resistance towards amikacin were observed in the eight Klebsiella spp. included in the 
collection, while 8% of the E. coli isolates showed reduced susceptibility to amikacin (Figure 
18) and (Appendix B; table 10-13). The prevalence of reduced susceptibility towards 
tobramycin and gentamicin was 56% and 44%. The prevalence of species specific reduced 
susceptibility was 57% and 45% towards tobramycin and gentamicin in E. coli and 50% and 
38% in Klebsiella spp., respectively. For kanamycin the prevalence of reduced susceptibility 
was 57% and for netilmicin 56%. The species specific results for E. coli showed 60% reduced 
susceptibility towards kanamycin and 57% reduced susceptibility towards netilmicin. The 





Table 13. Prevalence of reduced susceptibility to aminoglycosides in ESBLA-positive E. coli and Klebsiella 
spp. in collection 2 (n = 68).  





n = (%) 
Intermediate (I) 
n = (%) 
Resistant 
 (R) 
n = (%) 
 
I + R 
n = (%) 
Amikacin S < 8 R > 16 63 (93) 4 (6) 1 (1) 5 (7) 
Gentamicin S < 2 R > 4 38 (56) 1 (1) 29 (43) 30 (44) 
Tobramycin S < 2 R > 4 30 (44) 0 38 (56) 38 (56) 
Kanamycin1 S < 6 R > 24 29 (43) 15 (22) 24 (35) 39 (57) 
Netilmicin S < 2 R > 4 30 (44) 1 (1) 37 (55) 38 (56) 







Figure 18. Total and species specific reduced susceptibility to aminoglycosides in the ESBLA-positive E. 
coli and Klebsiella spp in collection 2. 
 
 
4.1.2.1 Broad-spectrum aminoglycoside resistance in collection 2 
In total the prevalence of isolates susceptible to all aminoglycosides in collection 2 
were 40%, including 39% of the E. coli and 50% of the Klebsiella spp. isolates, as shown in 
Fig 19. Five percent of the E. coli isolates, but none of the Klebsiella spp. showed reduced 
susceptibility to kanamycin only. The prevalence of reduced susceptibility to tobramycin, 
netilmicin, kanamycin, and gentamicin were 40%. Only one E. coli isolates was observed 
with reduced susceptibility to all aminoglycosides tested. 
 
 
Figure 19. Distribution of broad-spectrum aminoglycoside resistance in the ESBLA-positive isolates in 
collection 2, including results for E. coli and Klebsiella spp. T = tobramycin, N = netilmicin, G = 







































4.1.3 Collection 3: Carbapenem non-susceptible P. aeruginosa from K-res 
2007-09 
 
The Etest resistant profiles for the P. aeruginosa isolates included in collection 3 are 
listed in Table 14. The highest prevalence of reduced susceptibility observed in collection 3 
was 47% to netilmicin. The prevalence of reduced susceptibility to gentamicin and 
tobramycin was 38% and 18%, respectively. A total of 30% of the P. aeruginosa isolates 




Table 14. Etest resistant profile for the P. aeruginosa isolates in collection 3 (n = 77). 





n = (%) 
Intermediate (I) 
n = (%) 
Resistant 
 (R) 
n = (%) 
 
I + R 
n = (%) 
Amikacin S < 8 R > 16 54 (70) 8 (10) 15 (20) 23 (30) 
Gentamicin S < 4 R > 4 48 (62) 0 29 (38) 29 (38) 
Tobramycin S < 4 R > 4 63 (82) 0 14 (18) 14 (18) 
































4.1.3.1 Broad-spectrum aminoglycoside resistance in collection 3 
As shown in Figure 21, 53% of the P. aeruginosa isolates were susceptible to all 
aminglycosides tested. Resistance only to netilmicin was observed in 9% of the isolates, while 
8% were resistant to both netilmicin and gentamicin. Twelve percent of the isolates were in 




Figure 21. Distribution of broad-spectrum aminoglycoside resistance  in P. aeruginosa in collection 3. T = 



















4.2 Prevalence of clinical important aminoglycoside modifying 
enzymes (AMEs). 
 
4.2.1 Collection 1: E. coli and Klebsiella spp. from NORM 2009  
The total prevalence of the AMEs in E. coli and Klebsiella spp. with reduced 
susceptibility to different aminoglycosides in collection 1 is shown in Fig 22. The figures are 
shown in Appendix B; Table 16. The prevalence of the AAC(6’)-Ib enzyme, which confers 
resistance to amikacin and gentamicin C1a and C2  was 28% in collection 1;  24% in E. coli  
and 43% in Klebsiella spp. respectively. The prevalence of AAC(3)-II which confers 
resistance to gentamicin, tobramycin, and netilmicin was 79%. Both enzymes, AAC(6’)-Ib 
and AAC(3)-II, were in total detected in 16% of the isolates;  in 16% of the E. coli isolates 
and in 14% of the Klebsiella spp isolates.  
 
Three percent of the E. coli isolates and none of the Klebsiella spp. isolates harboured 
the ANT(2’’)-Ia enzyme, which confer resistance to gentamicin, tobramycin and kanamycin. 
AAC(3)-Ia which confer resistance to gentamicin and ANT(4’)-IIb which confers resistance 
to amikacin and tobramycin, were not detected in any of the isolates. In nine isolates (E. coli n 
= 6 and Klebsiella spp. n = 3) with an aminoglycoside resistant profile, none of the enzymes 
tested were detected. 
 
Figure 22. Prevalence of AMEs detected in E. coli and Klebsiella spp. with reduced susceptibility to 

















AAC(6')-Ib + AAC(3)-II 
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4.2.2. Collection 2: ESBLA-positive E. coli and Klebsiella spp. NORM 2007-
08 
Among the ESBLA-positive isolates from NORM 2007-08 with reduced susceptibility 
to different aminoglycosides, 34% of the isolates harboured the aac(6’)-Ib gene while the 
aac(3)-II gene was detected in 43% of the isolates. Both genes were detected in 21% of the 
isolates. The total prevalence of AMEs is shown in Figure 23 and the figures are shown in 
Appendix B; Table 17. Among E. coli, 37% of the isolates harboured aac(6’)-Ib while aac(3)-
II gene was detected in 43%. Both enzymes were present in 23% of the E. coli isolates. 
Among the Klebsiella spp. isolates the aac(6’)-Ib gene was detected in 13% of the isolates,  
while the aac(3)-II gene was detected in 38% of the isolates. None of the Klebsiella spp. 
isolats  were carrying both genes. aac(3)-Ia, ant(2’’)-Ia and ant(4)-IIb were not detected in 
collection 2. Three E. coli isolates with an aminoglycoside resistant profile did not come out 
positive of any of the enzymes tested. 
 
Figure 23. Prevalence of AMEs detected in ESBLA-positive E. coli and Klebsiella spp. with reduced 



















4.3 Detection of 16S rRNA methylases 
Eight isolates from collection 1 and 2, with high-level and broad-spectrum 
aminoglycoside resistance were screened for seven different 16S rRNA methylases by PCR. 
The isolates and results of PCRs are listed in Table 15. One blood culture isolate of E. coli 
(K65-50) included in the NORM 2009 collection (collection 1) from Ullevål hospital was 
positive for the 16S rRNA methylase gene rmtB. This positive result was confirmed by 
sequencing, and MLST revealed sequence type 617 (Table 16). 
 
 
Table 15. Results of screening for 16S rRNA methylases in isolates from collection 1 and 2 with high-level 
and broad-spectrum aminoglycoside resistance. Green = susceptible, Yellow = intermediate resistant and 
red = resistant. 
    Etest MIC µg/ml 












K64-02 E. coli Blood AHUS2 8 96 48 64 24 - 
K64-06 E. coli Urine AHUS2 12 6 4 8 3 - 
K64-07 K. pneumoniae Blood AHUS2 32 256 64 > 256 > 256 - 
K64-80 E. coli Blood Stavanger 12 16 48 > 256 32 - 
K65-01  E. coli Blood Stavanger 16 8 6 12 4 - 
K65-48 E. coli Blood Ullevål 16 128 96 128 32 - 
K65-50 E. coli Blood Ullevål > 256 256 384 > 256 > 256 rmtB 
K53-37 E. coli Blood Molde 32 4 64 256 24 - 
1AMK=amikacin, GEN=gentamicin, TOB=tobramycin, KAN=kanamycin, and NET=netilmicin 




Table 16. Allele numbers and sequence type for the rmtB-positive E. coli. 
  Allelic profile  
Ref. no Species adk fumC gyrB icd mdh purA recA ST 




From strain collection 3, 16 P. aeruginosa isolates with high-level and broad-spectrum 
aminoglycoside resistance were screened for 16S rRNA methylases. The 16S rRNA 
methylase gene rmtD was detected in one isolate from Stavanger University Hospital (K52-
27), a urine sample, and sequencing confirmed the result. The rest of the isolates were 
negative in the screening. The isolates and results of PCRs are listed in Table 17. MLST 




Table 17. Results of screening for 16S rRNA methylases in P. aeruginosa isolates from collection 3 with 
high-level and broad-spectrum aminoglycoside resistance.  Green = susceptible and red = resistant. 
    Etest MIC µg/ml 










K49-20 Sputum Østfold VIM2-2 > 256 > 1024 32 > 256 - 
K36-454 CVK8 AHUS3 VIM-4 > 256 192 128 > 256 - 
K36-464 Trachea AHUS3 VIM-4 > 256 128 128 > 256 - 
K45-32 Puss RH3 VIM-2 96 6 48 4 - 
K57-16 Decubitus Vestfold VIM-2 64 24 96 > 256 - 
K61-69 Abscess Stavanger VIM-1 6 6 0,75 6 - 
K44-245 Urine Vestfold IMP6-14 > 256 > 1024 > 1024 > 256 - 
K44-365 Sputum Vestfold MBL7-pos > 256 > 1024 > 1024 > 256 - 
K52-27 Urine Stavanger Porinloss, efflux 
 and AmpC-prod 
> 256 > 1024 > 1024 > 256 rmtD 
K61-73 Puss UNN3 Porinloss, efflux 
 and AmpC-prod 
> 256 24 64 > 256 - 
K71-59 Sputum RH3 Porinloss, efflux 
 and AmpC-prod 
> 256 24 6 32 - 
K44-57 Sputum Innlandet Porinloss, efflux 
 and AmpC-prod 
128 16 8 64 - 
K44-79 Trachea Haugesund Porinloss, efflux 
 and AmpC-prod 
64 32 48 > 256 - 
K44-80 Puss Haugesund Porinloss, efflux 
 and AmpC-prod 
64 32 48 > 256 - 
K52-42 Urine Innlandet Porinloss, efflux 
 and AmpC-prod 
24 96 32 > 256 - 
K52-63 Urine AHUS3 Porinloss, efflux 
 and AmpC-prod 
24 6 1 8 - 
1AMK=amikacin, GEN=gentamicin, TOB=tobramycin, and NET=netilmicin. 2VIM= Verona imipenemase. 
3AHUS= Akershus university hospital, RH=Oslo university hospital, Rikshospitalet, UNN=University hospital 
of North Norway. 4 Isolates from the same patient. 5 Isolates from the same patient. 6 IMP= Imipenemase. 7 





Table 18. Allele numbers and sequence type for the rmtD-positive P. aeruginosa. 
  Allelic profile  
Ref. no Species acsA aroE guaA mutL nuoD ppsA trpE ST 




4.4 Pulsed-field gel electrophoresis (PFGE) 
Eighteen E. coli isolates with elevated gentamicin resistance were selected for PFGE, 
to look for clusters that could suggest a dissemination of a successful Norwegian clone. PFGE 
banding patterns were obtained for 14 isolates (Figure 24). DNA from four of the isolates 




Figure 24. PFGE result of 18 E. coli isolates with elevated gentamicin resistance from different Norwegian 
hospitals. Lanes: 1 and 20, PFG marker; 2, K64-13; 3, K64-17;  4, K64-18; 5, K64-22; 6, K64-43; 7, K64-
44; 8, K64-46; 9, K64-49; 10, K64-55; 11, K64-70; 12, K65-3; 13, K65-6; 14, K65-8; 15, K65-21; 16, K65-
25; 17, K65-34; 18, K65-44; 19, K65-52. 
 
 
A dendogram (Figure 25) was made to illustrate a potential relatedness between the 
different isolates. Similar band patterns represent in general relatedness between isolates, but 

































































Figure 25. Dendogram to illustrate that there is no clonality between 14 E. coli isolates with elevated 





PFGE was also performed on 18 E. coli isolates from collection 1 were the Etest and 
the disk diffusion results for tobramycin did not correspond. Visual evaluation of the PFGE 
result showed diversity among the isolates (Figure 26). DNA from one isolate autodigested 
and no banding patterns were obtained. Since EUCAST breakpoints were changed after the 





Figure 26. PFGE result of 18 E. coli isolates with non-corresponding Etest and disk diffusion results for 
tobramycin. Lanes: 1 and 20, PFG marker; 2, K64-1; 3, K64-3;  4, K64-23; 5, K64-32; 6, K64-33; 7, K64-
39; 8, K64-43; 9, K64-53; 10, K64-54; 11, K64-66; 12, K64-67; 13, K65-1; 14, K65-3; 15, K65-23; 16, K65-
28; 17, K65-45; 18, K65-46; 19, K65-47. 
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4.5 Plasmid transfer studies 
PCR-based screening for different AMEs to give evidence for aminoglycoside 
resistance profile was negative in 12 isolates. Four isolates from collection 1 and 2 were 
chosen for plasmid transfer studies, to investigate if the resistance marker were located on a 
transferable element. Two of the isolates did not give transconjugants (K64-31 and K65-35). 
Transconjugants were obtained from K64-71 and K65-38, indicating a successful transfer of 
the resistance marker. All transconjugants from K64-71 and K65-38 were resistant to all 
aminoglycosides tested (Table 19). The transconjugation frequencies are shown in Appendix 
B; Table 18. 
 
Table 19. MIC for donors, recipient and transconjugants in the plasmid transfer studies. 
   Etest MIC µg/ml 
 Ref. no Species GEN1 TOB1 NET1 RIF1 
Recipient J53-2 E. coli 0,38 0,5 1 > 32 
Donor 1 K64-71 E. coli 32 64 32 NA2 
Donor 2 K65-38 E. coli 16 32 16 NA2 
Transconjugant K64-71 I E. coli 12 24 16 > 32 
Transconjugant K64-71 II E. coli 12 24 12 > 32 
Transconjugant K65-38 I E. coli 12 24 16 > 32 
Transconjugant K65-38 II E. coli 12 24 16 > 32 
1 GEN=gentamicin, TOB=tobramycin, NET=netilmicin, and RIF=rifampicin. 2 NA= not analysed 
 
Table 20. Allelic profile and sequence type of recipient strain J53-2 and donor strain K65-38, and partial 
allelic profile of donor strain K64-71 and transconjugants.  
   Allelic profile  
 Ref. no Species adk fumC gyrB icd mdh purA recA ST 
Recipient J53-2 E. coli 10 11 4 8 8 8 2 10 
Donor 1 K64-71 E. coli 6 4  16     
Donor 2 K65-38 E. coli 10 11 4 8 8 8 2 10 
Transconjugant K64-71 I E. coli 10 11  8     
Transconjugant K64-71 II E. coli 10 11  8     
Transconjugant K65-38 I E. coli 10 11  8     
Transconjugant K65-38 II E. coli 10 11  8     
 
 
MLST was performed on the recipient and donor K65-38 while partial MLST (fumC, adk, and 
icd) was performed on donor K64-71 and the transconjugants (Table 20). One of the donor 
strains (K65-38) turned out to have an identical sequence type as the recipient (J53-2). In this 
case, it was not possible to distinguish between transconjugants and donor. However, the 
donor K64-71 had a completely different partial allelic profile compared to J53-2. 
Transconjugants from K64-71 had the same partial allelic profile as J53-2 indicating a 
successful transfer of the resistance marker.  
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4.6 Comparison of three phenotypic methods for detecting 
reduced susceptibility to aminoglycosides 
 
A summary of the comparisons and retesting are listed in Appendix B. The resistant 
isolates are labelled R, the isolates with intermediate resistance are labelled I and the 
susceptible isolates are labelled S. 
 
 
Figure 27. Comparison of Etest and disk diffusion results in detecting reduced susceptibility to gentamicin 




4.6.1 Comparison of tests detecting reduced susceptibility to gentamicin 
One very major error was detected in collection 1 when comparing Etest (R) versus 
VITEK2 AST (S), but this result was not reproduced. The retesting classified the difference as 
a minor error, with Etest R and VITEK2 AST I. No very major errors were detected in 
collection 2. Major errors were not detected in collections 1 and 2, while all together 6 minor 
errors were detected. 
 
In collection 3, on the other hand, 16 isolates were classified as very major errors 
when comparing Etest (R) and disk diffusion (S), Figure 27. This result was reproduced in 
nine isolates, while six isolates gave identical results in both tests when retesting. Etest versus 
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reproduced, while five isolates became identical by retesting. Four isolates came out as very 
major errors, and reproduced when comparing VITEK2 AST and disk diffusion, Figure 28. 




Figure 28. Comparison of VITEK2 AST versus disk diffusion results in detecting reduced susceptibility to 




4.6.2 Comparison of tests detecting reduced susceptibility to tobramycin 
In collection 1, Etest detected one isolate as R while the disk diffusion test came out as 
S (Figure 29). This result was reproduced upon retesting, and considered a very major error.  
When comparing Etest and VITEK2 AST results (Figure 30), fourteen isolates were identified 
as R by Etest and S by VITEK2 AST also classified as very major errors. This result was 
reproduced in seven of these isolates upon retesting, five isolates were classified as minor 
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Figure 29. Comparison of Etest versus disk diffusion results in detecting reduced susceptibility to 
tobramycin in collection 1 (NORM 2009). 
 
No isolates in collection 2 gave very major errors. One isolate in collection 1 and one 
isolate in collection 2 were classified as major error, with VITEK2 AST S and disk diffusion 
R. Quite a number of isolates came out as minor errors. In collection 1, 24 isolates were 
reported as R by Etest and I by disk diffusion, and 17 isolates were R by Etest and I by 
VITEK2 AST. In collection 2, altogether 21 minor errors were demonstrated in the three 
comparisons. 
 
Figure 30. Comparison of Etest versus VITEK2 AST results in detecting reduced susceptibility to 
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In collection 3, one P. aeruginosa isolate was classified as very major error, both with 
Etest (R) versus disk diffusion (S) and VITEK2 AST (R) versus disk diffusion (S). Retesting 
of this isolate gave Etest S, disk diffusion S and VITEK2 AST R.  No minor errors were 
detected in collection 3. 
 
 
4.6.3 Comparison of tests detecting reduced susceptibility to amikacin 
MIC for amikacin was not available in the VITEK2 AST thus only Etest versus disk 
diffusion was compared. No very major errors or major errors were detected in collections 1 
and 2 when comparing the results of Etest and disk diffusion, but all together 13 minor errors 
were observed. In collection 3, one very major error was observed but changed to a minor 





Figure 31. Comparison of Etest and disk diffusion results in detecting reduced susceptibility to amikacin 
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Although aminoglycosides represent a small fraction of antibiotic consumption in 
Norway, it is still an important group of antibiotics in treating serious bacterial infections. 
Monitoring the level of aminoglycoside resistance is therefore an important task. The main 
mechanism causing aminoglycoside resistance is the presence of aminoglycoside modifying 
enzymes (AMEs). In addition, high level and broad-spectrum resistance to aminoglycosides is 
often associated with 16S rRNA methylases. Further, efflux mechanisms and impermeability 
of the cell wall may cause reduced susceptibility to aminoglycosides. 
 
This study has focused on resistance to different aminoglycosides in clinically 
important  isolates of Gram-negative bacteria from Norway, with emphasis on gentamicin, 
tobramycin, and amikacin. The prevalence of genes encoding clinically important AMEs and 
16S rRNA methylases has also been evaluated. In addition, phenotypic methods for detecting 
reduced susceptibility to aminoglycosides have been compared. 
 
5.1 Prevalence of aminoglycoside resistance  
5.1.1 Aminoglycoside resistance in E. coli and Klebsiella spp. in Norway 
An increase in the prevalence of resistance towards gentamicin has been observed in 
Norway over the past years. The Norwegian surveillance programme for antimicrobial 
resistance in human pathogens (NORM)(6) has reported an increased prevalence of reduced 
susceptibility to gentamicin from 1.2% in E. coli isolated from blood in 2000 to 4.0% in 2009 
and from 0.8% to 1.8% in Klebsiella spp. In this study isolates with reduced susceptibility to 
gentamicin and/or tobramycin from NORM 2009 (collection 1) were collected and the 
phenotypic testing was repeated. Surprisingly, 20% of the strains in collection 1 could not be 
reproduced using the Etest method. Thus, in this study the prevalence of reduced 
susceptibility to gentamicin in E. coli was 3.8% in blood culture isolates and 2.5% in urine 
isolates. Our figures differed slightly from the figures reported in NORM, where 4.0% of 
blood culture isolates and 3.1% in urinary tract isolates showed reduced susceptibility to 
gentamicin. This was also observed for Klebsiella spp. urine isolates where the prevalence of 
reduced susceptibility to gentamicin in NORM 2009 was 0.9%, while our data show a 
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prevalence of 0.7%. For blood culture isolates the prevalence of reduced susceptibility to 
gentamicin was the same (1.4%).  
 
The lack of reproducible results did affect the prevalence of tobramycin resistance to a 
greater extent than for gentamicin. In NORM 2009 the prevalence of reduced susceptibility to 
tobramycin in E. coli was reported to be 3.1% in blood culture isolates and 2.5% in urinary 
tract isolates. In our study the results were 4.1% in blood culture isolates and 2.6% in urinary 
tract isolates. For Klebsiella spp. the NORM 2009 figures were 1.8% in blood and 1.1% in 
urinary tract isolates, while our data showed 2.0% and 1.0%, respectively. When comparing 
the figures from NORM with our data, the major differences were in the intermediate resistant 
(I) category. This suggests that there is a difference between Etest and EUCAST disk 
diffusion in separating the different susceptibility categories (S-I-R). This was observed when 
comparing our Etest and EUCAST disk diffusion results (see below). In addition, the new 
EUCAST breakpoints for tobramycin were used in this study, while NORM 2009 is based on 
both the old method for disk diffusion and other breakpoints.  
 
Although 20% of the results could not be reproduced the overall prevalences of 
gentamicin resistance compared to the prevalence of tobramycin resistance were similar. 
Tobramycin was included in the panel of antibiotics investigated in NORM for the first time 
in 2009. It will be interesting to follow the surveillance of tobramycin in the coming years.  
 
There are no available national surveillance data regarding the prevalence of reduced 
susceptibility to neither amikacin nor netilmicin in Norway. Our study reveals low prevalence 
of reduced susceptibility to amikacin among the clinical isolates of E. coli and Klebsiella spp. 
(<0.6%). The rate of reduced susceptibility to netilmicin follows the same trends as for 
gentamicin and tobramycin with higher prevalence of reduced susceptibility in blood culture 
isolates (3.9% and 2.0%) compared to urinary tract isolates (2.6% and 1.0%) in E. coli and 
Klebsiella spp., respectively. However, the actual prevalence of reduced susceptibility to 
amikacin and netilmicin could be different as the isolates studied were selected based on 
reduced susceptibility to gentamicin and/or tobramycin. 
 
 The prevalence of aminoglycoside resistance in Norway is comparable to what is 
observed in other Scandinavian countries. The Swedish surveillance program SWEDRES(7) 
also reports an increasing trend in the prevalence of aminoglycoside resistance (gentamicin or 
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tobramycin). The prevalence of resistance in blood culture isolates in 2009 was 3.7% in E. 
coli and 1% in Klebsiella pneumoniae in Sweden, almost the same level as the Norwegian 
findings. In Denmark however, DANMAP(3), the Danish surveillance program, reports a 
prevalence of gentamicin resistance of 5% in E. coli blood culture isolates and 9% in K. 
pneumoniae. 
 
In comparison with other European countries the prevalence of aminoglycoside 
resistance is low in Scandinavia. The annual report for 2009 from the European Antimicrobial 
Resistance Surveillance Network(4) (EARS-Net) reveals a significant increase in the 
prevalence of aminoglycoside resistance in clinical isolates of E. coli in the period 2006-2009 
in 10 countries. Five of these countries (Hungary, Italy, Slovenia, Greece, and Spain) reported 
resistance rates higher than 10%. A significant increase in the prevalence of aminoglycoside 
resistance in clinical isolates of K. pneumoniae has been observed in 24 European countries. 
Even though the prevalence of resistance to aminoglycoside resistance in Norwegian isolates 
of Klebsiella spp. must be considered low, a significant increase has been observed in the 
period 2006-2009. Equivalent increase has been observed in Denmark, Estonia, France, and 
Portugal among other countries. Greece, Bulgaria and Lithuania report aminoglycoside 
resistance in K. pneumoniae above 50%. This suggests the likelihood that the prevalence of 
aminoglycoside resistance will continue to increase in Norway in the coming years. 
 
PFGE analyses of a subset of gentamicin, tobramycin, and netilmicin resistant E. coli 
isolates selected from hospitals in different regions in Norway, revealed a diverse population. 




5.1.2 Aminoglycoside resistance in ESBLA-positive E. coli and Klebsiella 
spp. in Norway 
The prevalence of reduced susceptibility among the confirmed ESBLA-positive 
isolates in collection 2 were as expected high compared to the isolates in collection 1. Fifty-
six percent were resistant to tobramycin, 44% were resistant to gentamicin, 55% were 
resistant to netilmicin while only 40% of the isolates tested were susceptible to all 
aminoglycosides. Seven percent of the isolates showed reduced susceptibility to amikacin. 
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This may suggest that amikacin could be a useful alternative drug in the treatment of 
infections with ESBLA-positive Enterobacteriaceae.    
 
The observed higher prevalence of aminoglycoside resistance in ESBLA-positive 
isolates suggests a link between the resistance genes. Genes that encode resistance to 
aminoglycoside resistance are located on a wide range of genetic elements such as integrons 
or transposable elements which have been associated with different multidrug-resistant 
ESBL-plasmids. Further, clonal spread is one of the major causes of the increase in 
prevalence of ESBLA-positive strains, and the blaCTX-M variant of ESBLs has been 
particularly successful(13). In Norway, CTX-M is also shown to be the dominant ESBLA 
enzyme (NORM 2009(6)) suggesting a link between blaCTX-M and aminoglycoside resistance 
genes. This is also shown in several studies which report a link between ESBLA and 
aminoglycoside resistance(20,29).  
 
Of note, the prevalence of ESBLA-positive K. pneumoniae increased from 5% in 2007 
to 14.6% in 2009 in Denmark (DANMAP(3)). This rapid increase may explain the high level 
of aminoglycoside resistance in K. pneumoniae, compared to the other Scandinavian 
countries. Worryingly, an increase in the prevalence of ESBLA in Norway is also observed 
(NORM reports) suggesting that the prevalence of aminoglycoside resistance is likely to 
increase in the coming years.  
 
Co-resistance to other antibiotic classes like fluoroquinolones, tetracyclines, and 
trimethoprim/sulfamethoxazole is frequently observed in ESBLA-positive strains. Thus, 
increase in ESBLA will likely be associated with an increase in resistance to other antibiotics 
due to linked resistance.  
 
 
5.1.3 Carbapenem non-susceptible Pseudomonas aeruginosa  
P. aeruginosa is not included annually in the Norwegian surveillance system, but 
blood-culture isolates of P. aeruginosa from 2002-2003 were analysed in 2005 (NORM 
2005(1)).  The susceptibility to gentamicin, tobramycin and amikacin was tested. All isolates 
tested were susceptible to tobramycin, while 1.6% of the isolates were resistant to amikacin 
and 1.7% of the isolates were resistant to gentamicin. 
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In our study, including P. aeruginosa with reduced susceptibility to carbapenems, 
more than 50% of the isolates were susceptible to all aminoglycosides tested, while 18% 
revealed reduced susceptibility to all aminoglycosides tested. Tobramycin is considered the 
most effective anti-pseudomonal aminoglycoside. Our data show a higher prevalence of 
reduced susceptibility to gentamicin (38%) compared to tobramycin (18%) and 30% reduced 
susceptibility to amikacin. This shows that in a collection of P. aeruginosa with reduced 
susceptibility to carbapenems, the prevalence of aminoglycoside resistance is much higher 
that in the general P.  aeruginosa population.   
 
Our collection of P. aeruginosa was selected based on reduced susceptibility to 
carbapenems of which seven isolates were known to produce carbapenemase. In P. 
aeruginosa, different mutations may confer antibiotic resistance(46). Several mechanisms are 
known to confer carbapenem-resistance, such as (I) inactivation or down regulation of 
carbapenem specific porins, (II) upregulation of AmpC β-lactamases and (III) upregulation of 
efflux by MexAB-OprM and other pumps. The MexAB-OprM pump may also act against 
aminoglycosides, and may be the explanation of the relatively high level of aminoglycoside 
resistance along with different AMEs in collection 3. Five of the eight carbapenemase-
positive P. aeruginosa strains included, showed high level and broad-spectrum 
aminoglycoside resistance. The genes encoding this resistance may be located on the same 
mobile genetic element harbouring the carbapenemase-gene. 
 
 
5.2 Prevalence of clinically important aminoglycoside modifying 
enzymes (AMEs) 
 
The AME AAC(3)-II, which confers resistance to gentamicin, tobramycin and 
netilmicin was the dominating enzyme (79%) detected in collection 1. All isolates with the 
aac(3)-II gene showed reduced susceptibility to gentamicin, tobramycin, netilmicin and 
kanamycin. AAC(6’)-Ib is considered the most clinically relevant acetyltransferase and 
confers resistance to amikacin and gentamicin C1a and C2(35). In collection 1, 28% of the 
strains was AAC(6’)-Ib positive. However, in our collection many of the isolates were 
susceptible to amikacin. As many as 42/53 of the isolates harbouring the aac(6’)-Ib gene had 
amikacin MIC categorised as susceptible. MICs detected were as low as 2 µg/ml, far below 
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the amikacin breakpoint at 8 µg/ml, This suggests that the susceptibility breakpoint for 
amikacin is not able to detect all isolates with AAC(6’)-Ib or that the level of amikacin 
resistance caused by AAC(6’)-Ib is low.  
 
A variant of the AAC(6’)-Ib enzyme, AAC(6’)-Ib-cr, is responsible for antibiotic 
resistance to two different classes of antimicrobial agents; fluoroquinolones and 
aminoglycosides(36). This enzyme is found as a gene cassette in different integrons and is 
associated with reduced susceptibility to fluoroquinolones. The VITEK2 Gram-negative 
susceptibility testing in our study detected a phenotypic ESBLA or ESBLM profile in 20% of 
the strains in collection 1, together with resistance to ciprofloxacin and trimethoprim/sulfa. 
This supports that genes encoding aminoglycoside-, fluoroquinolone-, and β-lactam 
resistance, are carried together on mobile genetic elements. In a study on isolates from 
NORM 2005 with reduced susceptibility to ciprofloxacin, all isolates positive for aac(6’)-Ib 
were of the aac(6’)-Ib-cr variant(25). In strain collection 1 the prevalence of ciprofloxacin-
resistance was 54%, indicating that the aac(6’)-Ib-cr variant also could be present in a large 
proportion of isolates in our collection. 
 
Also among the ESBLA-positive isolates in collection 2, AAC(3)-II was the 
dominating AME, detected in 71% of the isolates with reduced susceptibility to 
aminoglycosides. This corresponds well with the fact that all isolates positive for the aac(3)-II 
gene in collection 2 showed reduced susceptibility to gentamicin, tobramycin, and netilmicin. 
AAC(6’)-Ib was detected in 56% of the strains, and both enzymes were detected in 34%.  
 
 
5.3 Transfer of aminoglycoside resistance 
 Transfer of antibiotic resistance genes is well known to occur between bacteria. One of 
the isolates with  amonoglycoside resistant profile where no AMEs were detected (K64-71), 
gave successful transfer of the resistant marker  to the recipient strain J53-2. This indicates 
that the resistance marker is located on a transferable element. Genes coding for 
fluoroquinolone resistance, qnrS and qnrB have successfully been transferred between 
bacteria by transconjugation(21,23). K64-71 was resistant to ciprofloxacin and the transfer of 
the resistance marker may imply that the genes coding for aminoglycoside resistance in the 
plasmid transfer studies are located on the same transferable element as the gene coding for 
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the fluoroquinolone resistance. Further studies are required to identify the enzyme which 
inactivates the aminoglycosides. 
 
 
5.4 Detection of 16S rRNA methylases 
Plasmid-mediated 16S rRNA methylases have been found worldwide in the members 
of the family Enterobacteriaceae, P. aeruginosa and Acinetobacter baumannii(55). The 
presence of 16S rRNA methylases is associated with high level (MIC typically > 256 µg/ml) 
and broad-spectrum aminoglycoside resistance(16).In Gram-negative bacteria, seven enzymes 
have been described (ArmA, RmtA, RmtB, RmtC, RmtD, RmtE and NpmA)(14,18). armA 
isolated from Enterobacteriaceae and Acinetobacter baumannii and rmtB isolated from 
Enterobacteriaceae appear to be the most widespread genes, and have been detected primarily 
in Europe and Asia. rmtA and rmtC have only been reported from Japan in P. aeruginosa and 
Proteus mirabilis, respectively, while rmtD has been detected in P. aeruginosa isolates in 
Latin America(18). npmA has been detected in a clinical isolate of E. coli in Japan(18) and 
rmtE has been reported from a bovine-origin E. coli from USA(14). In China, a high 
prevalence of rmtB in E. coli has been reported(53) and coexistence of rmtB and armA has 
been detected in an isolate of Klebsiella pneumonia(54). There seems to be an association 
between 16S rRNA methylases and ESBL-coding genes, and the genes coding for these 
enzymes are sometimes located on the same conjugative plasmid.  
 
In this study, the methylase rmtB was detected in an E. coli strain (K65-50). This 
strain revealed high-level resistance to all aminoglycosides tested, and was in addition 
harbouring the ant(2’’)-1a gene coding for an aminoglycoside nucleotidyltransferase. 
However, no phenotypic ESBLA profile was detected in this strain, but the isolate was 
resistant to ciprofloxacin (MIC > 4 µg/ml). The 16S rRNA methylase gene armA has been 
identified in a carbapenemase-producing isolate of E. coli isolated in a Norwegian hospital in 
2009(38), but the 16S rRNA methylase rmtB has to our knowledge not been described in 
Norwegian isolates of Enterobacteriaceae previously. MLST analysis identified the rmtB 
positive E. coli as sequence type (ST)617, belonging to the sequence type complex STC10. 
Studies have revealed that the spread of blaCTX-M is attributed to different ST-types belonging 
to (STC)10, such as ST10, ST48, ST168 and ST617(33). STC 10 represents some of the 
major STs responsible for blaCTX-M-15, blaCTX-M-14, and blaCTX-M-9 dissemination.  
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 In this study, disks of arbekacin and isepamycin (kindly donated by Mr Keiko 
Kawaguchi, BD, Japan) were included in the disk diffusion screening. Arbekacin, an 
aminoglycoside synthesized from dibekacin (syntethic derivate of kanamycin), is widely used 
in Japan and has shown a wide spectrum of antibacterial activity. Most noteworthy is 
arbekacin’s activity against methicillin-resistant Staphylococcus aureus(47). A unique 
characteristic of 16S rRNA methylases is the high level resistance to arbekacin. Of all isolates 
tested (collection 1 and 2) only the isolate harbouring the rmtB gene displayed no inhibitory 
zone around the arbekacin disk confirming that arbekacin could be a useful substrate for 
detection of 16S rRNA methylases. 
 
Among the P. aeruginosa isolates in collection 3, one isolate was positive for 16S 
rRNA methylases. The 16S rRNA methylase rmtD was identified in a urine isolate (K52-27). 
MLST analysis revealed the allelic profile of sequence type (ST) 277. No carbapenemases 
were identified in this isolate, and the reduced susceptibility to carbapenems was likely to be 
due to porin loss, efflux or increased AmpC-production. rmtD was firstly reported  in Brazil 
in a clinical strain of P. aeruginosa which also produced the metallo-β-lactamase SPM-1 (Sao 
Paulo metallo- β-lactamase)(15). SPM-1 is carried on a class 1 integron which also harbours 
aminoglycoside resistance genes(51). Interestingly, Silva et al reported in a study from Brasil 




5.5 Comparison of three phenotypic methods for detecting 
reduced susceptibility to aminoglycosides  
 
Different phenotypic methods are available for detecting reduced susceptibility to 
antibiotics. In Norway the most common method used is the EUCAST disk diffusion method. 
In addition, automated systems like VITEK2 are often used. It is vital that the methods reveal 
comparable and consistent results.  
 
When comparing the methods for detecting reduced susceptibility to the 
aminoglycosides investigated in the Enterobacteriaceae strains in collections 1 and 2, the main 
inconsistencies were related to tobramycin. Preliminary analyses of the comparison between 
Etest and disk diffusion revealed several very major errors. During the project period the 
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EUCAST disk diffusion breakpoints (mm-zones) were changed from R<12 and S>15 to R<13 
and S>16. When comparing Etest and disk diffusion using the new breakpoints, the number of 
very major errors was reduced from five to one. Still, a considerable number of 24 minor 
errors were observed. In contrast, when the methods for detecting reduced susceptibility to 
gentamicin and amikacin were compared, only minor errors were found. This indicates better 
correlation between the methods, and also supports the current breakpoints. The majority of 
minor errors were observed when comparing amikacin Etest and disk diffusion.  
 
Comparison of methods to detect reduced susceptibility to aminoglycosides in P. 
aeruginosa gave a different picture. In this species the methods to detect reduced 
susceptibility to tobramycin and amikacin mainly gave minor errors. However, the methods to 
detect reduced susceptibility to gentamicin showed a number of reproducible very major 
errors in all three comparisons. Interestingly, few minor errors were detected for gentamicin. 
 
The high prevalence of very major errors in comparison of methods detecting reduced 
susceptibility to gentamicin (P. aeruginosa) and minor errors in methods detecting reduced 
susceptibility to tobramycin (Enterobacteriaceae) may indicate a need for evaluation of the 
breakpoints. The gold standard in establishing minimum inhibitory concentrations is micro 
broth dilution, and the isolates giving errors in this comparison should be retested using this 
method. In this manner, the minor errors could be confirmed or invalidated, and give support 
to a potential change in breakpoints. When comparing Etest and disk diffusion with the 
automated VITEK2 AST, several reproducible very major errors and minor errors were 
detected. This emphasises the importance of quality control of automated systems, and for the 
manufacturers to calibrate the anti-susceptibility cards regularly. 
 
From a clinical point of view, very major errors in phenotypic methods for detecting 
reduced susceptibility to antibiotics may result in treatment failure. Incorrect reporting of 
susceptibility testing results may also contribute to development of resistance. It is therefore 
of utmost importance that medical microbiology laboratories perform appropriate testing. This 
study has also shown that breakpoints are not static, and have to be monitored and evaluated 
regularly.   
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6. Concluding remarks 
 
• The level of aminoglycoside resistance in Norwegian clinical isolates of E. coli and 
Klebsiella spp. is still low, but has increased over the last years. 
• 60% of the ESBLA-positive E. coli and Klebsiella spp. isolates and 47% of the 
carbapenem non-susceptible P. aeruginosa isolates tested were resistant to at least one 
aminoglycoside. This shows that resistance mechanisms are linked together resulting 
in multi-drug resistance limiting treatment options. 
• AAC(3)-II and AAC(6’)-Ib are the dominating aminoglycoside modifying enzymes in 
Norwegian Enterobacteriaceae.  
• 16S rRNA methylases (rmtB and rmtD) are present in Norwegian isolates of E. coli 
and P. aeruginosa.  





In order to overcome the worrisome development of increased resistance to antibiotic 
resistance in general and aminoglycoside resistance in particular, continued national and 
international surveillance programs are crucial. Norwegian medical microbiology laboratories 
have to ensure that methods used for detecting antibiotic resistance are validated. Hospitals 
have to ensure that appropriate infection control practices are implemented to limit continued 
spread of resistant microbes. Resources have to be made available for continued research on 
antibiotic resistance and development of new antimicrobial agents. Finally, prudent use of 
antimicrobial agents must be called for, and use of broad-spectrum antibiotics must be limited 
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Table 1. Distribution of gentamicin susceptibility pattern of E. coli and Klebsiella spp included in NORM 
2009. S = susceptible, I = intermediate resistant and R = resistant. 
Gentamicin: BD S BD I/R Oxoid S Oxoid I/R S I/R (Total) 
E. coli blood 409 1 / 18 917 5 / 31   
E. coli urine 257 2 / 10 837 9 / 14   
E. coli total 666 3 / 28 1754 14 / 45 2420 17 / 73 (90) 
       
Klebsiella spp. blood 194 0 / 6 369 1 / 1   
Klebsiella spp. urine 315 1 / 2 683 2 / 4   






Table 2. Distribution of tobramycin susceptibility pattern of E. coli and Klebsiella spp included in NORM 
2009. S = susceptible, I = intermediate resistant and R = resistant. 
Tobramycin: BD S BD I/R Oxoid S Oxoid I/R S I/R (Total) 
E. coli blood 407 4 / 17 931 5 / 17   
E. coli urine 257 2 / 10 844 9 / 7   
E. coli total 664 6 / 27 1775 14 / 24 2439 20 / 51 (71) 
       
Klebsiella spp. blood 191 2 / 7 365 5 / 1   
Klebsiella spp. urine 312 3 / 3 684 5 / 0   












Table 3. General prescription for mastermix. 
General Mastermix Amount 
JumpStart™ REDTaq® ReadyMix™ PCR Reaction Mix (Sigma-Aldrich) 
Primer F 50 pmole/ µl (Eurogentec S.A., Belgium) 









Table 4. Prescription for mastermix for 16S meth multiplex #1-PCR 
16S meth multiplex #1 (rmtB, rmtC, armA) Mastermix Amount 
JumpStart™ REDTaq® ReadyMix™ PCR Reaction Mix (Sigma-Aldrich) 
rmtB F primer 50 pmole/ µl (Eurogentec S.A.) 
rmtB R primer 50 pmole/ µl (Eurogentec S.A.) 
rmtC F primer 50 pmole/ µl (Eurogentec S.A.) 
rmtC R primer 50 pmole/ µl (Eurogentec S.A.) 
armA F primer 50 pmole/ µl (Eurogentec S.A.) 














Table 5. PCR programs applied in this study. 
PCR  Initial 
denaturation 
Cycles Denaturation Primer 
annealing 
Elongation Final elongation 
16S rDNA 95ºC / 1 min 30 95ºC / 30 sec 55ºC / 30 sec 72ºC / 1 min 72ºC / 7 min → 
4°C → ∞ 
aac(6’)-Ib 95ºC / 5 min 30 95ºC / 15 sec 58ºC / 15 sec 72ºC / 30 sec 72ºC / 4 min → 
4°C → ∞ 
aac(3)-Ia 96ºC / 5 min 30 96ºC / 30 sec 55ºC / 30 sec 72ºC / 30 sec 72ºC / 4 min → 
4°C → ∞ 
aac(3)-II 95ºC / 5 min 30 95ºC / 15 sec 58ºC / 15 sec 72ºC / 30 sec 72ºC / 4 min → 
4 °C → ∞ 
ant(2’’)-Ia 96ºC / 5 min 30 96ºC / 30 sec 58ºC / 30 sec 72ºC / 45 sec 72ºC / 7 min → 
4 °C → ∞ 
ant(4’)-IIb 96ºC / 5 min 30 96ºC / 30 sec 60ºC / 30 sec 72ºC / 30 sec 72ºC / 5 min → 
4 °C → ∞ 
 
rmtA 96ºC / 5 min 30 96ºC / 30 sec 55ºC / 30 sec 72ºC / 1 min 72ºC / 5 min → 
4 °C → ∞ 
rmtB/rmtC/ 
armA 
96ºC / 5 min 30 96ºC / 30 sec 55ºC / 30 sec 72ºC / 1 min 72ºC / 5 min → 
4 °C → ∞ 
rmtD 96ºC / 5 min 30 96ºC / 30 sec 55ºC / 30 sec 72ºC / 1 min 72ºC / 5 min → 
4 °C → ∞ 
rmtE 96ºC / 5 min 30 96ºC / 30 sec 50ºC / 30 sec 72ºC / 1 min 72ºC / 7 min → 
4 °C → ∞ 
npmA 96ºC / 5 min 30 96ºC / 30 sec 55ºC / 30 sec 72ºC / 1 min 72ºC / 5 min → 
4 °C → ∞ 
MLST E. coli 95ºC / 2 min 30 95ºC / 1 min 54ºC / 1 min 72ºC / 2 min 72ºC / 5 min → 
4 °C → ∞ 
MLST P. 
aeruginosa 
96ºC / 1 min 30 96ºC / 1 min 55ºC / 1 min 72ºC / 1 min 72ºC / 10 min → 
4 °C → ∞ 







Table 6. Primers used in this study 







AGA GTT TGA TCM TGG CTC AG  
 
Modified fD1 and fD2 
(Weisburg et al.,1991) 
16SrDNA-R 
 





Modified from rP1, rP2, 
rP3(Weisburg et al.,1991) 
aac(6')-lb-F TTG CGA TGC TCT ATG AGT GGC TA 
aac(6')-lb-R CTC GAA TGC CTG GCG TGT TT 
aac(6’)
-Ib 
482 Park CH. AAC 2006 
aac(3)-Ia_F ATG GGC ATC ATT CGC ACA TGT 
AGG 
aac(3)-Ia_R TTA GGT GGC GGT ACT TGG GTC 
aac(3)-
Ia 
465 Hujer KM, 2006 AAC 
aac(3)-II-F TGA AAC GCT GAC GGA GCC TC 
aac(3)-II-B GTC GAA CAG GTA GCA CTG AG 
aac(3)-
II 
370 Jensen et al JAC 
2006:58.101-107 
ant(2'')-Ia_F ATG GAC ACA ACG CAG GTC GC 
ant(2'')-Ia_R TTA GGC CGC ATA TCG CGA CC 
ant(2’’)
-Ia 
535 Hujer KM, 2006 AAC 
ant(4')-IIb_F TAT CTC GGC GGC GGT CGA GT 
ant(4')-IIb_R CAC GCG GGG AAA CGC GAG AA 
ant(4’)-
IIb 
364 This study 
rmtB-F GCT TTC TGC GGG CGA TGT AA 
rmtB-R ATG CAA TGC CGC GCT CGT AT 
rmtB 173 Doi Y and Arakawa Y. 
CID. 2007 
rmtC-F CGA AGA AGT AAC AGC CAA AG 
rmtC-R ATC CCA ACA TCT CTC CCA CT 
rmtC 711 Doi Y and Arakawa Y. 
CID. 2007 
armA-F ATT CTG CCT ATC CTA ATT GG 
armA-R ACC TAT ACT TTA TCG TCG TC 
armA 315 Doi Y and Arakawa Y. 
CID. 2007 
rmtA-F CTA GCG TCC ATC CTT TCC TC 
rmtA-R TTG CTT CCA TGC CCT TGC C 
rmtA 635 Doi Y and Arakawa Y. 
CID. 2007 
rmtD-F CGG CAC GCG ATT GGG AAG C 
rmtD-R CGG AAA CGA TGC GAC GAT 
rmtD 401 Doi Y and Arakawa Y. 
CID. 2007 
rmtE-F ATG AAT ATT GAT GAA ATG GTT 
GC 
rmtE-R TGA TTG ATT TCC TCC GTT TTT G 
rmtE 818 Davis et al. AAC 2010  
npmA-F CTC AAA GGA ACA AAG ACG G 
npmA-R GAA ACA TGG CCA GAA ACT C 
npmA 640 Doi Y and Arakawa Y. 
CID. 2007 
adk-F ATT CTG CTT GGC GCT CCG GG 
adk-R CCG TCA ACT TTC GCG TAT TT 
adk 536 
funC-F TCA CAG GTC GCC AGC GCT TC 
funC-R GTA CGC AGC GAA AAA GAT TC 
funC 469 
gyrB-F TCG GCG ACA CGG ATG ACG GC 
ATC AGG CCT TCA CGC GCA TC 
gyrB-R ATC AGG CCT TCA CGC GCA TC 
gyrB 460 
icd-F ATG GAA AGT AAA GTA GTT GTT 
CCG 
icd-R GGA CGC AGC AGG ATC TGT T 
icd 518 
mdh-F ATG AAA GTC GCA GTC CTC GGC 
GCT GCT GGC GG 
mdh-R TTA ACG AAC TCC TGC CCC AGA 
GCG TAT CTT TCT T 
mdh 452 
purA-F CGC GCT GAT GAA AGA GAT GA 
purA-R CAT ACG GTA AGC CAC GCA GA 
purA 478 
recA-F  CGC ATT CGC TTT ACC CTG ACC 














acsA-F ACC TGG TGT ACG CCT CGC TGA C 
acsA-R GAC ATA GAT GCC CTG CCC CTT 
GAT 
acsA 390 
aroE-F TGG GGC TAT GAC TGG AAA CC 
aroE-R TAA CCC GGT TTT GTG ATT CCT 
ACA 
aroE 492 






GAA CGC CTG GCT GGT CTT GTG 
GTA 
  
mutL-F CCA GAT CGC CGC CGG TGA GGT G 
mutL-R CAG GGT GCC ATA GAG GAA GTC 
mutL 442 
nuoD-F ACC GCC ACC CGT ACT G 
nuoD-R TCT CGC CCA TCT TGA CCA 
nuoD 366 
ppsA-F GGT CGC TCG GTC AAG GTA GTGG 
ppsA-R GGG TTC TCT TCT TCC GGC TCG 
TAG 
ppsA 370 
trpE-F GCG GCC CAG GGT CGT GAG 






Table 7. General prescription for sequencing mastermix. 
Sequencing Mastermix (pr. reaction) Amount 
Big Dye v 3.1 (Applied Biosystems) 
5x sequencing buffer (Applied Biosystems) 










Figure 1. The sizes of the bands of the Kb+ ladder (Invitrogen) 
 
 
Figure 2. Low range PFG marker (New England Biolabs) labelled with the fragment sizes (kb) 
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Table 8. Bacterial growth media, reagents and solutions used in this study. 
Green agar plates 
Tryptose Blood Agar Base (Oxoid) 
Lactose (Oxoid) 
Bromthymol blue solution 0,2 % (Merck) 
ddH2O 
Green agar plates w/ 100 mg/ml ampicillin 
Tryptose Blood Agar Base (Oxoid) 
Lactose (Oxoid) 
Bromthymol blue solution 0,2 % (Merck) 
Ampicillin (Bristol-Myers Squibb) 
ddH2O 
Freeze broth 




50 mg of NNN'N'-tetrametyl-p-phenylene 
diamine dihydroklorid (Sigma-Aldrich)  
5 ml dH2O. 
Mueller-Hinton (MH) II agar 
Mueller-Hinton II agar BBL (BD) 
ddH2O 
0.85 % saline 
8.5 g Natrium chloride (Merck) 
ddH2O to 1 litre 
10X TBE buffer 
108 g Tris Base (Sigma-Aldrich) 
55 g Boric acid (Sigma-Aldrich) 
40 ml 0,5 M EDTA pH 8.0 (Sigma-Aldrich) 
ddH2O to 1 litre 
BHI-broth 
52 g Brain Heart Infusion (Oxoid) 
15 g Bacto agar (Difco) 
ddH2O to 1 litre 
PIV-buffer 
10 mM Tris-HCl pH 7.6 (Sigma-Aldrich)   
1 M NaCl (Merck)   
0.45 % saline 
4.5 g Natrium chloride (Merck) 
ddH2O to 1 litre 
Lysis-buffer (for 5 plugs) 
10 ml basic buffer 
0.02 g sodium deoxycholate (Sigma-Aldrich) 
0.5  g N-laurolsylsarcosine (Sigma-Aldrich) 
0.01 g lysozyme (Sigma-Aldrich) 
1 µl RNase One (10U/ µl) (Promega) 
Basic-buffer 
0,5 % Brij 58 (Merck) 
1 M Tris-HCl pH 8 (Sigma-Aldrich) 




0.5 M EDTA pH 9-9.5 (Sigma-Aldrich) 
1 % N-laurolsylsarcosine (Sigma-Aldrich) 
TE-buffer 
10 mM Tris-HCl pH 8 (Sigma-Aldrich) 
0.1 mM EDTA (Sigma-Aldrich) 
Xba I mixture 
Buffer 4 (10x) (New England BioLabs) 
BSA (100x) (New England BioLabs) 
Xba I (20U/µl) (New England BioLabs) 
ddH2O  
Restriction enzyme buffer w/ bovine serum 
albumin (BSA). 
Buffer 4 (10x) (New England BioLabs) 
BSA (100x) (New England BioLabs) 
ddH2O 
LB-broth 
25 g Difco LB Broth (BD) 
ddH2O to 1 litre 
LB-agar w/ 100 µg/ml rifampicin 
40 g Difco LB Agar (BD) 
Rifampicin 100 µg/ml (Sigma-Aldrich) 
ddH2O to 1 litre 
LB-agar w/ 6 µg/ml gentamicin 
40 g Difco LB Agar (BD) 
Gentamicin µg/ml (Sigma-Aldrich) 
ddH2O to 1 litre 
LB-agar w/ 100 µg/ml rifampicin and 6 µg/ml 
gentamicin 
40 g Difco LB Agar (BD) 
Rifampicin 100 µg/ml (Sigma-Aldrich) 
Gentamicin µg/ml (Sigma-Aldrich) 
ddH2O to 1 litre 
EtBr-solution 
50 µl EtBr  (Sigma-Aldrich) 






Appendix B    
 
Table 1. Clinical breakpoints used in this study. 
 E. coli and Klebsiella spp. P. aeruginosa 








Amikacin1 S < 8 R > 16 S < 8 R > 16 S < 8 R > 16 S > 18 R < 15 
Gentamicin1 S < 2 R > 4 S < 2 R > 4 S < 4 R > 4 S > 15 R < 15 
Tobramycin1 S < 2 R > 4 S < 2 R > 4 S < 4 R > 4 S > 16 R < 16 
Kanamycin2 S < 6 R > 24 S < 6 R > 24   
Netilmicin1 S < 2 R > 4 S < 2 R > 4 S < 4 R > 4 S > 12 R < 12 
1 EUCAST breakpoints. 2 CLSI breakpoints 
 
E. coli and Klebsiella spp. NORM 2009  
Table 2. Prevalence of reduced susceptibility to aminoglycosides in blood culture isolates of E. coli  collected 
through NORM 2009, performed by Etest (n = 1381).  






n =  
Intermediate 
(I)  
n = (%) 
Resistant 
(R) 
 n = (%) 
 
I + R 
n = (%) 
Amikacin1 S < 8 R > 16 1373 7 (0.5) 1 (0.1)  8 (0.6) 
Gentamicin1 S < 2 R > 4 1329 0  52 (3.8) 52 (3.8) 
Tobramycin1 S < 2 R > 4 1324 3 (0.2) 54 (3.9) 57 (4.1) 
Kanamycin2 S < 6 R > 24 1341 21 (1.5) 19 (1.4) 40 (2.9) 
Netilmicin1 S < 2 R > 4 1327 11 (0.8) 43 (3.1) 54 (3.9) 
1 EUCAST breakpoints. 2 CLSI breakpoints 
 
Table 3. Prevalence of reduced susceptibility to aminoglycosides in urinary tract isolates of E.coli  collected 
through NORM 2009,  performed by Etest (n = 1129).  








n = (%) 
Resistant 
(R) 
n = (%) 
 
I + R 
n = (%) 
Amikacin1 S < 8 R > 16 1128 1 (0.1) 0 1 (0.1) 
Gentamicin1 S < 2 R > 4 1101 0 28 (2.5) 28 (2.5) 
Tobramycin1 S < 2 R > 4 1100 2 (0.2) 27 (2.4) 29 (2.6) 
Kanamycin2 S < 6 R > 24 1109 14 (1.2) 6 (0.5) 20 (1.7) 
Netilmicin1 S < 2 R > 4 1100 9 (0.8) 20 (1.8) 29 (2.6) 
1 EUCAST breakpoints. 2 CLSI breakpoints 
 
Table 4. Prevalence of reduced susceptibility to aminoglycosides in blood culture isolates of Klebsiella spp.  
collected through NORM 2009, performed by Etest  (n = 571).  









n = (%) 
Resistant 
(R) 
 n = (%) 
 
I + R 
n = (%) 
Amikacin1 S < 8 R > 16 569 1 (0.2) 1 (0.2) 2 (0.4) 
Gentamicin1 S < 2 R > 4 563 0 8 (1.4) 8 (1.4) 
Tobramycin1 S < 2 R > 4 560 2 (0.4) 9 (1.6) 11 (2) 
Kanamycin2 S < 6 R > 24 563 3 (0.5) 5 (0.9) 8 (1.4) 
Netilmicin1 S < 2 R > 4 560 6 (1.1) 5 (0.9) 11 (2) 
1 EUCAST breakpoints. 2 CLSI breakpoints 
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Table 5. Prevalence of reduced susceptibility to aminoglycosides in urinary tract isolates of Klebsiella spp.  
collected through NORM 2009, performed by Etest  (n = 1007).  








n =  
Resistant 
(R) 
 n =  
 
I + R 
n = (%) 
Amikacin1 S < 8 R > 16 1005 0 2 (0.2) 2 (0.2) 
Gentamicin1 S < 2 R > 4 1000 0 7 (0.7) 7 (0.7) 
Tobramycin1 S < 2 R > 4 997 4 (0.4) 6 (0.6) 10 (1) 
Kanamycin2 S < 6 R > 24 1003 2 (0.2) 2 (0.2) 4 (0.4) 
Netilmicin1 S < 2 R > 4 997 8 (0.8) 2 (0.2) 10 (1) 
1 EUCAST breakpoints. 2 CLSI breakpoints 
 
Table 6. Prevalence of reduced susceptibility to aminoglycosides in blood culture isolates of  E. coli collected 
through NORM 2009, performed by disk diffusion (n = 1381). 






n =  
Intermediate 
(I) 
n = (%) 
Resistant 
(R) 
n = (%) 
 
I + R 
n = (%) 
Amikacin1 S > 16 R < 13 1378 2 (0.1) 1 (0.1) 3 (0.2) 
Gentamicin1 S > 17 R < 14 1329 1 (0.1) 51 (3.7) 52 (3.8) 
Tobramycin1 S > 16 R < 13 1326 13 (0.9) 42 (3) 55 (3.9) 
Kanamycin2 S > 18  R < 14 1344 22 (1.6) 15 (1.1) 37 (2.7) 
Netilmicin1 S > 15 R < 12 1335 22 (1.6) 24 (1.7) 46 (3.3) 
Streptomycin2 S > 15  R < 12 1326 13 (0.9) 42 (3) 55 (3.9) 
1 EUCAST breakpoints. 2 CLSI breakpoints 
 
Table 7. Prevalence of reduced susceptibility to aminoglycosides in urinary tract isolates of  E. coli collected 
through NORM 2009, performed by disk diffusion (n = 1129). 






n =  
Intermediate 
(I) 
n = (%) 
Resistant 
(R) 
n = (%) 
 
I + R 
n = (%) 
Amikacin1 S > 16 R < 13 1128 1 (0.1) 0 1 (0.1) 
Gentamicin1 S > 17 R < 14 1101 1 (0.1) 27 (2.4) 28 (2.5) 
Tobramycin1 S > 16 R < 13 1102 8 (0.7) 19 (1.7) 27 (2.4) 
Kanamycin2 S > 18  R < 14 1103 17 (1.5) 9 (0.8) 26 (2.3) 
Netilmicin1 S > 15 R < 12 1103 16 (1.4) 10 (0.9) 26 (2.3) 
Streptomycin2 S > 15  R < 12 1102 8 (0.7) 19 (1.7) 27 (2.4) 
1 EUCAST breakpoints. 2 CLSI breakpoints 
 
Table 8. Prevalence of reduced susceptibility to aminoglycosides in blood culture isolates of  Klebsiella spp. 
collected through NORM 2009, performed by disk diffusion (n = 571). 






n =  
Intermediate 
(I) 
n = (%) 
Resistant 
(R) 
n = (%) 
 
I + R 
n = (%) 
Amikacin1 S > 16 R < 13 570 1 (0.2) 0 1 (0.2) 
Gentamicin1 S > 17 R < 14 563 0 8 (1.4) 8 (1.4) 
Tobramycin1 S > 16 R < 13 562 3 (0.5) 6 (1.1) 9 (1.6) 
Kanamycin2 S > 18  R < 14 562 1 (0.2) 8 (1.4) 9 (1.6) 
Netilmicin1 S > 15 R < 12 564 4 (0.7) 3 (0.5) 7 (1.2) 
Streptomycin2 S > 15  R < 12 567 0 4 (0.7) 4 (0.7) 





Table 9. Prevalence of reduced susceptibility to aminoglycosides in urinary tract isolates of  Klebsiella spp. 
collected through NORM 2009, performed by disk diffusion (n = 1007). 






n =  
Intermediate 
(I) 
n = (%) 
Resistant 
(R) 
n = (%) 
 
I + R 
n = (%) 
Amikacin1 S > 16 R < 13 1005 0 2 (0.2) 2 (0.2) 
Gentamicin1 S > 17 R < 14 1000 0 7 (0.7) 7 (0.7) 
Tobramycin1 S > 16 R < 13 999 4 (0.4) 4 (0.4) 8 (0.8) 
Kanamycin2 S > 18  R < 14 1003 2 (0.2) 2 (0.2) 4 (0.4) 
Netilmicin1 S > 15 R < 12 1004 1 (0.1) 2 (0.2) 3 (0.3) 
Streptomycin2 S > 15  R < 12 999 3 (0.3) 5 (0.5) 8 (0,8) 





Collection 2: ESBL-positive E. coli and Klebsiella spp. NORM 2007-2008  
(n = 68) 
 
 
Table 10. Prevalence of reduced susceptibility to aminoglycosides ESBL-positive E. coli and Klebsiella spp. in 
collection 2, performed by Etest (n = 68). 
  Number of isolates 





n = (%) 
Intermediate 
(I) 
n = (%) 
Resistant 
(R) 
n = (%) 
Amikacin1 S < 8  R > 16 63 (93) 4 (6) 1 (1) 
Gentamicin1 S < 2 R > 4 38 (56) 1 (1) 29 (43) 
Tobramycin1 S < 2 R > 4 30 (44) 0 38 (56) 
Kanamycin2  S < 6  R > 24 29 (43) 15 (22) 24 (35) 
Netilmicin1 S < 2 R > 4 30 (44) 1 (1) 37 (55) 
1 EUCAST breakpoints. 2 CLSI breakpoints 
 
 
Table 11. Prevalence of reduced susceptibility to aminoglycosides ESBL-positive E. coli and Klebsiella spp. in 
collection 2, performed by disk diffusion (n = 68). 






n = (%) 
Intermediate 
(I) 
n = (%) 
Resistant 
(R) 
n = (%) 
Amikacin1 S > 16 R < 13 67 (99) 1 (1) 0 
Gentamicin1 S > 17 R < 14 39 (57) 0 29 (43) 
Tobramycin1 S > 16 R < 13 30 (44) 10 (15) 28 (41) 
Kanamycin2 S > 18 R < 14 33 (49) 7 (10) 28 (41) 
Netilmicin1 S > 15 R < 12 35 (51) 23 (34) 10 (15) 
Streptomycin2 S > 15 R < 12 21 (31) 12 (18) 35 (51) 










Table 12. The prevalence of reduced susceptibility to aminoglycosides in ESBL-positive E. coli in collection 2, 
performed by Etest (n = 60).  






n = (%) 
Intermediate 
(I) 
n = (%) 
Resistant 
 (R) 
n = (%) 
I + R 
 
n = (%) 
Amikacin1 S < 8 R > 16 55 (92) 4 (7) 1 (1) 5 (8) 
Gentamicin1 S < 2 R > 4 33 (55) 1 (1) 26 (44) 27 (45) 
Tobramycin1 S < 2 R > 4 26 (43) 0 34 (57) 34 (57) 
Kanamycin2 S < 6 R > 24 24 (40) 13 (22) 23 (38) 46 (60) 
Netilmicin1 S < 2 R > 4 26 (43) 1 (1) 33 (56) 34 (57) 
1 EUCAST breakpoints. 2 CLSI breakpoints 
 
Table 13. The prevalence of reduced susceptibility to aminoglycosides in ESBL-positive Klebsiella spp.  in 
collection 2, performed by Etest (n = 8).  






n = (%) 
Intermediate 
(I) 
n = (%) 
Resistant 
 (R) 
n = (%) 
I + R 
 
n = (%) 
Amikacin1 S < 8 R > 16 8 (100) 0 0 0 
Gentamicin1 S < 2 R > 4 5 0 3 3 (38) 
Tobramycin1 S < 2 R > 4 4 (50) 0 4 (50) 4 (50) 
Kanamycin2 S < 6 R > 24 5 (62) 2 (25) 1 (13) 3 (38) 
Netilmicin1 S < 2 R > 4 4 (50) 0 4 (50) 4 (50) 
1 EUCAST breakpoints. 2 CLSI breakpoints 
 
 
Collection 3: Carbapenem non-susceptible Pseudomonas aeruginosa from 
K-res 2007-2009 collection (n = 77) 
 
 
Table 14. The prevalence of reduced susceptibility to aminoglycosides in carbapenem non-susceptible P. 
aeruginosa in collection 3, performed by Etest (n = 77).  






n = (%) 
Intermediate 
(I) 
n = (%) 
Resistant 
 (R) 
n = (%) 
Amikacin1 S < 8 R > 16 54 (70) 8 (10) 15 (20) 
Gentamicin1 S < 4 R > 4 48 (62) 0 29 (38) 
Tobramycin1 S < 4 R > 4 63 (82) 0 14 (18) 
Netilmicin1 S < 4 R > 4 41 (53) 0 36 (47) 
1 EUCAST breakpoints 
 
 
Table 15. The prevalence of reduced susceptibility to aminoglycosides in carbapenem non-susceptible P. 
aeruginosa in collection 3, performed by disk diffusion (n = 77).  








n = (%) 
Intermediate 
(I) 
n = (%) 
Resistant 
(R) 
n = (%) 
Amikacin1 S > 18 R < 15 59 (77) 4 (5) 14 (18) 
Gentamicin1 S > 15 R < 15 64 (83) 0 13 (17) 
Tobramycin1 S > 16 R < 16 64 (83) 0 13 (17) 
Netilmicin1 S > 12 R < 12 61 (79) 0 16 (21) 
1 EUCAST breakpoints 
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Prevalence of clinical important aminoglycoside modifying 
enzymes (AMEs) 
  
Collection 1: E. coli and Klebsiella spp. from NORM 2009  
Table 16. The prevalence of AMEs detected in E. coli and Klebsiella spp. with reduced susceptibility to 
aminoglycosides collected through NORM 2009 in collection 1. 
 
aac(6')-Ib 
n = (%) 
 
aac(3)-II 
n = (%) 
 
aac(3)-Ia 
n = (%) 
 
ant(2'')-Ia 
n = (%) 
ant(4')-IIb 
n = (%) 
aac(6')-Ib + 
aac(3)-II 
n = (%) 
Total n = 107 30 (28) 84 (79) 0 3 (3) 0 17 (16) 
E. coli n = 86 21 (24) 70 (81) 0 3 (3) 0 14 (16) 
Klebsiella spp. 
n = 21 9 (43) 14 (67) 0 0 0 3 (14) 
 
 
Collection 2: ESBL-positive E. coli and Klebsiella spp. NORM 2007-2008  
 
Table 17. The prevalence of AMEs detected in ESBL positive E. coli and Klebsiella spp. with reduced 




n = (%) 
aac(3)- 
II 
n = (%) 
aac(3)- 
Ia 
n = (%) 
ant(2'')- 
Ia 
n = (%) 
ant(4')- 
IIb 
n = (%) 
aac(6')-Ib + 
aac(3)-II 
n = (%) 
Total n = 41 23 (56) 29 (71) 0 0 0 14 (34) 
E. coli n = 37 22 (59) 26 (70) 0 0 0 14 (38) 










Donor clinical isolate Transconjugant per donor Transconjugant per recipient 
K64-71 (E. coli) 7 x 10-3 6 x 10-3 
K65-38 (E. coli) 1.4 x 10-2 7 x 10-3 
1 Transconjugation frequencies were calculated by dividing the number of transconjugants by the number of 











Summary of comparison of phenotypic methods 
 
 
Collection 1: E. coli and Klebsiella spp. from NORM 2009 (n = 137) 
 
Tobramycin: 
 Very major error Major error Minor error 
Etest R – Disk S  Etest R – Disk I  Etest vs 
disk 1 (1 reproduced) 
 
 24  
Etest R – VITEK2 
S 
 Etest R – 
VITEK2  I 
 Etest vs 
VITEK2 
14 (7 reproduced) 
Retesting: 
2 R/S – R/R 
2 R/S – I/I 
1 R/S – R/I 
2 R/S – I/I 
 17  
Disk S – VITEK2 
R 
VITEK2  S – 
Disk R 
VITEK2  R – 
Disk I 









 Very major error Major error Minor error 
Etest R – Disk S  Etest R – Disk I  Etest vs 
disk 0  2  
Etest R – VITEK2 
S 
 Etest R – 
VITEK2  I 
 Etest vs 
VITEK2 
1 (0 reproduced) 
Retesting: 
R/S – R/I 
 0  
Disk S – VITEK2 
R 
VITEK2  S – 
Disk R 
VITEK2  R – 
Disk I 









 Very major error Major error Minor error 














 Very major error Major error Minor error 
Etest R – Disk S  Etest R – Disk I  Etest vs 
disk 0  10  
Etest R – VITEK2 
S 
 Etest R – 
VITEK2  I 
 Etest vs 
VITEK2 
0  4  
Disk S – VITEK2 
R 
VITEK2  S – 
Disk R 
VITEK2  R – 
Disk I 









 Very major error Major error Minor error 




0  0 1 
Etest R – VITEK2 
S 
 Etest R – 
VITEK2  I 
 Etest vs 
VITEK2 
0  0  
Disk S – VITEK2 
R 
VITEK2  S – 
Disk R 
VITEK2  R – 
Disk I 









 Very major error Major error Minor error 

















Collection 3: Carbapenem non-susceptible Pseudomonas aeruginosa from K-res 2007-




 Very major error Major error Minor error 
Etest R – Disk S  Etest R – Disk I  Etest vs 
disk 1 (not reproduced) 
 
 0  
Etest R – VITEK2 
S 
 Etest R – 
VITEK2  I 
 Etest vs 
VITEK2 
0  0  
Disk S – VITEK2 
R 
VITEK2  S – 
Disk R 
VITEK2  R – 
Disk I 




1 (1 reproduced) 
 





 Very major error Major error Minor error 
Etest R – Disk S  Etest R – Disk I  Etest vs 
disk 16 (9 reproduced) 
Retesting: 
6 R/S – S/S 
1 R/S – R/R 
 0  
Etest R – VITEK2 
S 
 Etest R – 
VITEK2  I 
 Etest vs 
VITEK2 
12 (7 reproduced) 
Retesting: 
5 R/S – S/S 
 0  
Disk S – VITEK2 
R 
VITEK S – Disk 
R 
VITEK2  R – 
Disk I 




4 (4 reproduced) 
 





 Very major error Major error Minor error 




1 (0 reproduced) 
1 R/S – I/S 





















































R < 14 S > 17  
Figure 1. Comparison of Etest versus disk diffusion results in detecting reduced susceptibility to gentamicin in  
collection 1 
 
















































    S < 2 R > 4
 



































R < 14 S > 17
 
Figure 3. Comparison of VITEK2 AST versus disk diffusion results in detecting reduced susceptibility to gentamicin 
in collection 1 
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R < 14 S > 17
 













































S < 2 R > 4
 
Figure 5. Comparison of Etest versus VITEK2 AST results in detecting reduced susceptibility to gentamicin in 
collection 2. 
 






























R < 14 S > 17
 
Figure 6. Comparison of VITEK2 AST versus disk diffusion results in detecting reduced susceptibility to gentamicin 
in collection 2. 
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Figure 7. Comparison of Etest versus disk diffusion results in detecting reduced susceptibility to gentamicin in 
collection 3. 













































Figure 8. Comparison of Etest versus VITEK2 AST results in detecting reduced susceptibility to gentamicin in 
collection 3. 













































S < 2 R > 4
 
Figure 9. Comparison of Etest versus VITEK2 AST results in detecting reduced susceptibility to tobramycin in  
collection 1. 
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R < 13 S > 16
 
Figure 10. Comparison of VITEK2 AST versus disk diffusion results in detecting reduced susceptibility to tobramycin 
in collection 1. 
 





































S > 16R < 13
 
Figure 11. Comparison of Etest versus disk diffusion results in detecting reduced susceptibility to tobramycin in  
collection 2. 






































     S < 2               R > 4
 
Figure 12. Comparison of Etest versus VITEK2 results in detecting reduced susceptibility to tobramycin 
in collection 2. 
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R < 13 S > 16
 
Figure 13. Comparison of VITEK2 versus disk diffusion results in detecting reduced susceptibility to tobramycin in 
collection 2. 
 















































Figure 14. Comparison of Etest versus disk diffusion results in detecting reduced susceptibility to tobramycin in 
collection 3. 
 













































Figure 15. Comparison of Etest versus VITEK2 AST results in detecting reduced susceptibility to tobramycin in 
collection 3. 
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Figure 16. Comparison of VITEK2 AST versus disk diffusion results in detecting reduced susceptibility to tobramycin 
in collection 3. 
 
Figure 17. Comparison of Etest versus disk diffusion results in detecting reduced susceptibility to amikacin in 
collection 1. 






































  R < 13      S > 16
 
Figure 18. Comparison of Etest versus disk diffusion results in detecting reduced susceptibility to amikacin in  
collection 2. 
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   R < 15      S > 18
 
Figure 19. Comparison of Etest versus disk diffusion results in detecting reduced susceptibility to amikacin in  
collection 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
